

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2007 (01.02.2007)

PCT

(10) International Publication Number
WO 2007/013944 A3

(51) International Patent Classification:

A61K 38/20 (2006.01)	A61P 17/06 (2006.01)
A61P 35/00 (2006.01)	A61P 25/00 (2006.01)
A61P 43/00 (2006.01)	A61P 1/00 (2006.01)
A61P 19/02 (2006.01)	

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2006/028106

(22) International Filing Date: 20 July 2006 (20.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/700,951	20 July 2005 (20.07.2005)	US
60/771,260	8 February 2006 (08.02.2006)	US

(71) Applicant (for all designated States except US): ZYMO-GENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SHEPPARD, Paul, O. [US/US]; 13532 278th Drive NE, Granite Falls, WA 98252 (US).

(74) Agents: WALSH, Brian, J. et al.; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 18 May 2007

{Continued on next page}

(54) Title: USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS



(57) Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.

WO 2007/013944 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/028106

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K38/20 A61P35/00 A61P43/00 A61P19/02 A61P17/06
A61P25/00 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/023862 A (ZYMOGENETICS INC [US]; BRADY LOWELL J [US]; KLUCHER KEVIN M [US]; CHAN) 17 March 2005 (2005-03-17) claims, page 57, line 4 – page 60, line 29 page 45, line 1 – page 46, line 22 -----	1-33
X	US 2005/037012 A1 (BRADY LOWELL J [US] ET AL) 17 February 2005 (2005-02-17) claims paragraphs [0139] – [0146], [0107] – [0115] -----	1-33
X	WO 02/086087 A (ZYMOGENETICS INC [US]) 31 October 2002 (2002-10-31) claims page 40, line 1 – line 4 page 49, line 9 – page 52, line 22 -----	9-27, 29-33

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 March 2007

Date of mailing of the international search report

23/03/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Böhmerova, Eva

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/028106

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 02/092762 A (IMMUNEX CORP [US]; BAUM PETER R [US]; MOSLEY BRUCE A [US]; KETCHEM RAN) 21 November 2002 (2002-11-21) claims page 44, line 9 - line 17</p> <p>-----</p>	29-31
X	<p>WO 03/066002 A (UNIV NEW JERSEY MED [US]; KOTENKO SERGEI [US]; GALLAGHER GRANT [US]) 14 August 2003 (2003-08-14) page 178, paragraph 3 - page 179, paragraph 2 page 189, paragraph 2 - page 191, paragraph 2 page 209, paragraph 1 - paragraph 2</p> <p>-----</p>	9-27, 29-33
A	<p>FRANCIS G E ET AL: "PEGYLATION OF CYTOKINES AND OTHER THERAPEUTIC PROTEINS AND PEPTIDES: THE IMPORTANCE OF BIOLOGICAL OPTIMISATION OF COUPLING TECHNIQUES" INTERNATIONAL JOURNAL OF HEMATOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 68, no. 1, July 1998 (1998-07), pages 1-18, XP000791226 ISSN: 0925-5710 the whole document</p> <p>-----</p>	1-6
P, X	<p>WO 2006/012644 A (ZYMOGENETICS INC [US]; DOYLE SEAN [US]; KLUCHER KEVIN M [US]; SIVAKUMA) 2 February 2006 (2006-02-02) the whole document</p> <p>-----</p>	1-33

CLAIMS

What is claimed is:

1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide selected from the group of SEQ ID NOs: 163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.
2. The method of claim 1 wherein the polypeptide further comprises polyethylene glycol.
3. The method of claim 2 wherein the polyethylene glycol is covalently linked amino-terminally to the polypeptide.
4. The method of claim 2 wherein the polyethylene glycol is about 20kD, 30kD, or 40 kD.
5. The method of claim 2 wherein the polyethylene glycol is linear or branched.
6. The method of claim 2 wherein the polyethylene glycol is monomethoxy-PEG propionaldehyde.
7. The method of claim 1 wherein the patient is a mammal.
8. The method of claim 7 wherein the patient is a human.
9. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs: 163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer,

melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

10. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175; and

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

11. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

12. The method of claim 11 wherein the second polypeptide is an Interferon.

13. The method of claim 12 wherein the second polypeptide is Interferon-alpha, Interferon-beta, or Interferon-gamma.

14. A method of inhibiting the progressive of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95%

sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

15. A method of inhibiting the progression of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

16. A method of delaying the onset of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

17. A method of delaying the onset of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

18. A method of reducing the severity of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOS:163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

19. A method of reducing the severity of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOS:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

20. A method of inhibiting at least one of the conditions or symptoms of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOS:163, 165, 167, 169, 171, 173 and 175, wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's

lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

21. A method of inhibiting at least one of the conditions or symptoms of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of B-cell lymphomas, chronic lymphocytic leukemia, acute lymphocytic leukemia, Non-Hodgkin's lymphomas, multiple myeloma, acute myelocytic leukemia, chronic myelocytic leukemia, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, melanoma, thyroid carcinoma, malignant gliomas, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, ovarian cancer, testicular cancer, Kaposi's sarcoma, and bone cancer.

22. A method of inhibiting at least one of the conditions or symptoms of non-Hodgkin's lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the at least one of the conditions or symptoms is selected from the group of painless swelling of a lymph node in the neck, armpit or groin, night sweats, unexplained fever, weight loss, and excessive tiredness.

23. A method of inhibiting at least one of the conditions or symptoms of non-Hodgkin's lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide; and

a pharmaceutically acceptable vehicle;

wherein the at least one of the conditions or symptoms is selected from the group of painless swelling of a lymph node in the neck, armpit or groin, night sweats, unexplained fever, weight loss, and excessive tiredness.

24. A method of inhibiting at least one of the conditions or symptoms of multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the at least one of the conditions or symptoms is selected from the group of back pain, loss of height, anaemia, kidney damage, repeated respiratory infections, and hypercalcaemia.

25. A method of inhibiting at least one of the conditions or symptoms of multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide; and

a pharmaceutically acceptable vehicle;

wherein the at least one of the conditions or symptoms is selected from the group of back pain, loss of height, anaemia, kidney damage, repeated respiratory infections, and hypercalcaemia.

26. A method of inhibiting at least one of the conditions or symptoms of head and neck tumours comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the at least one of the conditions or symptoms is selected from the group of an ulcer or sore area in the head or neck that does not heal within a few weeks, difficulty in swallowing, trouble with breathing or speaking, a numb feeling in the mouth, nose bleeds, persistent earache, difficulty in hearing, and swelling or lump in the mouth or neck.

27. A method of inhibiting at least one of the conditions or symptoms of head and neck tumours comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide; and

a pharmaceutically acceptable vehicle;

wherein the at least one of the conditions or symptoms is selected from the group of an ulcer or sore area in the head or neck that does not heal within a few weeks, difficulty in swallowing, trouble with breathing or speaking, a numb feeling in the mouth, nose bleeds, persistent earache, difficulty in hearing, and swelling or lump in the mouth or neck.

28. A method of treating an autoimmune disorder comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the autoimmune disorder is selected from the group of multiple sclerosis, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and psoriasis.

29. A method of treating an autoimmune disorder comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175, wherein the autoimmune disorder is selected from the group of multiple sclerosis, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and psoriasis.

30. A method of an autoimmune disorder comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of multiple sclerosis, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and psoriasis.

31. A method of inhibiting the progression of an autoimmune disorder comprising administering to a patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;

a second polypeptide;

a pharmaceutically acceptable vehicle; and

wherein the cancer is selected from the group of multiple sclerosis, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and psoriasis.

32. A method of delaying a multiple sclerosis relapse in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;
a pharmaceutically acceptable vehicle.

33. A method of reducing the severity of a multiple sclerosis relapse in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a formulation comprising:

a polypeptide having at least 95% sequence identity with a sequence selected from the group of SEQ ID NOs:163, 165, 167, 169, 171, 173 and 175;
a pharmaceutically acceptable vehicle.

Sheet 1 of 8




Figure 1




Figure 2

Sheet 2 of 8




Figure 3




Figure 4

Sheet 3 of 8




Figure 5A




Figure 5B

Sheet 4 of 8




Figure 6




Figure 7

Sheet 5 of 8




Figure 8




Figure 9

Sheet 6 of 8






Figure 10

Sheet 7 of 8

**Figure 11**

Sheet 8 of 8**Figure 12**

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> USE OF TRUNCATED CYSTEINE IL28 AND IL29
MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS

<130> 05-23PC

<150> US 60/700,951
<151> 2005-07-20

<150> US 60/771,260
<151> 2006-02-08

<160> 175

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 734
<212> DNA
<213> Homo sapiens

<220>
<221> sig_peptide
<222> (53)...(127)

<221> mat_peptide
<222> (128)...(655)

<221> CDS
<222> (53)...(655)

<400> 1
tgggtacac cctcagactg tttcttctgc tgacaaagac cagagatcag ga atg aaa 58
Met Lys
-25

cta gac atg act ggg gac tgc acg cca gtg ctg gtg atg gcc gca 106
Leu Asp Met Thr Gly Asp Cys Thr Pro Val Leu Val Leu Met Ala Ala
-20 -15 -10

gtg ctg acc gtg act gga gca gtt cct gtc gcc agg ctc cac ggg gct 154
Val Leu Thr Val Thr Gly Ala Val Pro Val Ala Arg Leu His Gly Ala
-5 1 5

ctc ccg gat gca agg ggc tgc cac ata gcc cag ttc aag tcc ctg tct 202
Leu Pro Asp Ala Arg Gly Cys His Ile Ala Gln Phe Lys Ser Leu Ser
10 15 20 25

cca cag gag ctg cag gcc ttt aag agg gcc aaa gat gcc tta gaa gag 250
Pro Gln Glu Leu Gln Ala Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu
30 35 40

tcg ctt ctg ctg aag gac tgc agg tgc cac tcc cgc ctc ttc ccc agg 298
Ser Leu Leu Leu Lys Asp Cys Arg Cys His Ser Arg Leu Phe Pro Arg
45 50 55

acc tgg gac ctg agg cag ctg cag gtg agg gag cgc ccc atg gct ttg 346

Thr Trp Asp Leu Arg Gln Leu Gln Val Arg Glu Arg Pro Met Ala Leu
 60 65 70

gag gct gag ctg gcc ctg acg ctg aag gtt ctg gag gcc acc gct gac 394
 Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Thr Ala Asp
 75 80 85

act gac cca gcc ctg gtg gac gtc ttg gac cag ccc ctt cac acc ctg 442
 Thr Asp Pro Ala Leu Val Asp Val Leu Asp Gln Pro Leu His Thr Leu
 90 95 100 105

cac cat atc ctc tcc cag ttc cgg gcc tgt atc cag cct cag ccc acg 490
 His His Ile Leu Ser Gln Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr
 110 115 120

gca ggg ccc agg acc cgg ggc cgc ctc cac cat tgg ctg tac cgg ctc 538
 Ala Gly Pro Arg Thr Arg Gly Arg Leu His His Trp Leu Tyr Arg Leu
 125 130 135

cag gag gcc cca aaa aag gag tcc cct ggc tgc ctc gag gcc tct gtc 586
 Gln Glu Ala Pro Lys Lys Glu Ser Pro Gly Cys Leu Glu Ala Ser Val
 140 145 150

acc ttc aac ctc ttc cgc ctc acg cga gac ctg aat tgt gtt gcc 634
 Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Asn Cys Val Ala
 155 160 165

agt ggg gac ctg tgt gtc tga ccctcccacc agtcatgcaa cctgagattt 685
 Ser Gly Asp Leu Cys Val *

170 175

tatttataaa ttagccactt gtcttaattt attgccaccc agtcgctat 734

<210> 2
 <211> 200
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)...(25)

<400> 2
 Met Lys Leu Asp Met Thr Gly Asp Cys Thr Pro Val Leu Val Leu Met
 -25 -20 -15 -10
 Ala Ala Val Leu Thr Val Thr Gly Ala Val Pro Val Ala Arg Leu His
 -5 1 5
 Gly Ala Leu Pro Asp Ala Arg Gly Cys His Ile Ala Gln Phe Lys Ser
 10 15 20
 Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys Arg Ala Lys Asp Ala Leu
 25 30 35
 Glu Glu Ser Leu Leu Lys Asp Cys Arg Cys His Ser Arg Leu Phe
 40 45 50 55
 Pro Arg Thr Trp Asp Leu Arg Gln Leu Gln Val Arg Glu Arg Pro Met
 60 65 70
 Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Thr
 75 80 85
 Ala Asp Thr Asp Pro Ala Leu Val Asp Val Leu Asp Gln Pro Leu His
 90 95 100
 Thr Leu His His Ile Leu Ser Gln Phe Arg Ala Cys Ile Gln Pro Gln
 105 110 115

Pro Thr Ala Gly Pro Arg Thr Arg Gly Arg Leu His His Trp Leu Tyr
 120 125 130 135
 Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Pro Gly Cys Leu Glu Ala
 140 145 150
 Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Asn Cys
 155 160 165
 Val Ala Ser Gly Asp Leu Cys Val
 170 175

<210> 3
 <211> 856
 <212> DNA
 <213> Homo sapiens

<220>
 <221> sig_peptide
 <222> (98) ... (154)

<221> mat_peptide
 <222> (155) ... (700)

<221> CDS
 <222> (98) ... (700)

<400> 3
 aattacctt tcactttaca cacatcatct tggattgccc atttgcgtg gctaaaaagc 60
 agagccatgc cgctgggaa gcagttgcga tttagcc atg gct gca gct tgg acc 115
 Met Ala Ala Ala Trp Thr
 -15

gtg gtg ctg gtg act ttg gtg cta ggc ttg gcc gtg gca ggc cct gtc 163
 Val Val Leu Val Thr Leu Val Leu Gly Leu Ala Val Ala Gly Pro Val
 -10 -5 1

ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac att ggc agg 211
 Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg
 5 10 15

tcc aaa tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg 259
 Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg
 20 25 30 35

gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct 307
 Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser
 40 45 50

cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag 355
 Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Gln Val Arg Glu
 55 60 65

cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg 403
 Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu
 70 75 80

gag gcc gct gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt 451
 Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu
 85 90 95

cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgg atc cag cct 499
 His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro

100	105	110	115
cag ccc aca gca ggg ccc agg ccc cg ^g ggc cgc ctc cac cac tgg ctg 547			
Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu			
120	125	130	
cac cg ^g ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag 595			
His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu			
135	140	145	
gca tct gtc acc ttc aac ctc ttc cgc ctc ac ^g cga gac ctc aaa 643			
Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys			
150	155	160	
tat gtg gcc gat ggg aac ctg tgt ctg aga ac ^g tca acc cac cct gag 691			
Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr His Pro Glu			
165	170	175	
tcc acc tga caccacac cttattatg cgctgagccc tactcattcc 740			
Ser Thr *			
180			
ttaattattt tcctctcacc ctttatttat gaagctgcag ccctgactga gacataggc 800			
ttagttttt gtttacttt tatacattat gcacaaataa acaacaagga attgga 856			
<210> 4			
<211> 200			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SIGNAL			
<222> (1)...(19)			
<400> 4			
Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val Leu Gly Leu			
-15 -10 -5			
Ala Val Ala Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys			
1 5 10			
Gly Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala			
15 20 25			
Ser Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys			
30 35 40 45			
Asn Trp Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg			
50 55 60			
Leu Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala			
65 70 75			
Leu Thr Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp			
80 85 90			
Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu			
95 100 105			
Gln Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly			
110 115 120 125			
Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu			
130 135 140			
Ser Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu			
145 150 155			
Leu Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg			
160 165 170			
Thr Ser Thr His Pro Glu Ser Thr			
175 180			

<210> 5
 <211> 734
 <212> DNA
 <213> Homo sapiens

<220>
 <221> sig_peptide
 <222> (53) ... (127)

<221> mat_peptide
 <222> (128) ... (655)

<221> CDS
 <222> (53) ... (655)

<400> 5
 tgggtacac cctcagatgt tttttctgc tgacaaagac cagagatcag ga atg aaa 58
 Met Lys
 -25

cta gac atg acc ggg gac tgc atg cca gtg ctg gtg atg gcc gca 106
 Leu Asp Met Thr Gly Asp Cys Met Pro Val Leu Val Leu Met Ala Ala
 -20 -15 -10

gtg ctg acc gtg act gga gca gtt cct gtc gcc agg ctc cgc ggg gct 154
 Val Leu Thr Val Thr Gly Ala Val Pro Val Ala Arg Leu Arg Gly Ala
 -5 1 5

ctc ccg gat gca agg ggc tgc cac ata gcc cag ttc aag tcc ctg tct 202
 Leu Pro Asp Ala Arg Gly Cys His Ile Ala Gln Phe Lys Ser Leu Ser
 10 15 20 25

cca cag gag ctg cag gcc ttt aag agg gcc aaa gat gcc tta gaa gag 250
 Pro Gln Glu Leu Gln Ala Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu
 30 35 40

tcg ctt ctg ctg aag gac tgc aag tgc cgc tcc cgc ctc ttc ccc agg 298
 Ser Leu Leu Lys Asp Cys Lys Cys Arg Ser Arg Leu Phe Pro Arg
 45 50 55

acc tgg gac ctg agg cag ctg cag gtg agg gag cgc ccc gtg gct ttg 346
 Thr Trp Asp Leu Arg Gln Leu Gln Val Arg Glu Arg Pro Val Ala Leu
 60 65 70

gag gct gag ctg gcc ctg acg ctg aag gtt ctg gag gcc acc gct gac 394
 Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Thr Ala Asp
 75 80 85

act gac cca gcc ctg ggg gat gtc ttg gac cag ccc ctt cac acc ctg 442
 Thr Asp Pro Ala Leu Gly Asp Val Leu Asp Gln Pro Leu His Thr Leu
 90 95 100 105

cac cat atc ctc tcc cag ctc cgg gcc tgt atc cag cct cag ccc acg 490
 His His Ile Leu Ser Gln Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr
 110 115 120

gca ggg ccc agg acc cgg ggc cgc ctc cac cat tgg ctg cac cgg ctc 538
 Ala Gly Pro Arg Thr Arg Gly Arg Leu His His Trp Leu His Arg Leu
 125 130 135

cag gag gcc cca aaa aag gag tcc cct ggc tgc ctc gag gcc tct gtc 586
 Gln Glu Ala Pro Lys Lys Glu Ser Pro Gly Cys Leu Glu Ala Ser Val
 140 145 150

acc ttc aac ctc ttc cgc ctc acg cga gac ctg aat tgt gtt gcc 634
 Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Asn Cys Val Ala
 155 160 165

agc ggg gac ctg tgt gtc tga cccttccgccc agtcatgcaa cctgagattt 685
 Ser Gly Asp Leu Cys Val *
 170 175

tatttataaaa tttagccactt ggcttaattt attgccaccc agtcgctat 734

<210> 6
<211> 200
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)...(25)

<400> 6
 Met Lys Leu Asp Met Thr Gly Asp Cys Met Pro Val Leu Val Leu Met
 -25 -20 -15 -10
 Ala Ala Val Leu Thr Val Thr Gly Ala Val Pro Val Ala Arg Leu Arg
 -5 1 5
 Gly Ala Leu Pro Asp Ala Arg Gly Cys His Ile Ala Gln Phe Lys Ser
 10 15 20
 Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys Arg Ala Lys Asp Ala Leu
 25 30 35
 Glu Glu Ser Leu Leu Lys Asp Cys Lys Cys Arg Ser Arg Leu Phe
 40 45 50 55
 Pro Arg Thr Trp Asp Leu Arg Gln Leu Gln Val Arg Glu Arg Pro Val
 60 65 70
 Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Thr
 75 80 85
 Ala Asp Thr Asp Pro Ala Leu Gly Asp Val Leu Asp Gln Pro Leu His
 90 95 100
 Thr Leu His His Ile Leu Ser Gln Leu Arg Ala Cys Ile Gln Pro Gln
 105 110 115
 Pro Thr Ala Gly Pro Arg Thr Arg Gly Arg Leu His His Trp Leu His
 120 125 130 135
 Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Pro Gly Cys Leu Glu Ala
 140 145 150
 Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Asn Cys
 155 160 165
 Val Ala Ser Gly Asp Leu Cys Val
 170 175

<210> 7
<211> 633
<212> DNA
<213> Mus musculus

<220>
<221> sig_peptide
<222> (22)...(105)

<221> mat_peptide
<222> (106)...(630)

<221> CDS
<222> (22)...(630)

<400> 7
tcacagaccc cggagagcaa c atg aag cca gaa aca gct ggg ggc cac atg 51
Met Lys Pro Glu Thr Ala Gly Gly His Met
-25 -20

ctc ctc ctg ctg ttg cct ctg ctg gcc gca gtg ctg aca aga acc 99
Leu Leu Leu Leu Pro Leu Leu Ala Ala Val Leu Thr Arg Thr
-15 -10 -5

caa gct gac cct gtc ccc agg gcc acc agg ctc cca gtg gaa gca aag 147
Gln Ala Asp Pro Val Pro Arg Ala Thr Arg Leu Pro Val Glu Ala Lys
1 5 10

gat tgc cac att gct cag ttc aag tct ctg tcc cca aaa gag ctg cag 195
Asp Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Lys Glu Leu Gln
15 20 25 30

gcc ttc aaa aag gcc aag gat gcc atc gag aag agg ctg ctt gag aag 243
Ala Phe Lys Ala Lys Asp Ala Ile Glu Lys Arg Leu Leu Glu Lys
35 40 45

gac ctg agg tgc agt tcc cac ctc ttc ccc agg gcc tgg gac ctg aag 291
Asp Leu Arg Cys Ser Ser His Leu Phe Pro Arg Ala Trp Asp Leu Lys
50 55 60

cag ctg cag gtc caa gag cgc ccc aag gcc ttg cag gct gag gtg gcc 339
Gln Leu Gln Val Gln Glu Arg Pro Lys Ala Leu Gln Ala Glu Val Ala
65 70 75

ctg acc ctg aag gtc tgg gag aac atg act gac tca gcc ctg gcc acc 387
Leu Thr Leu Lys Val Trp Glu Asn Met Thr Asp Ser Ala Leu Ala Thr
80 85 90

atc ctg ggc cag cct ctt cat aca ctg agc cac att cac tcc cag ctg 435
Ile Leu Gly Gln Pro Leu His Thr Leu Ser His Ile His Ser Gln Leu
95 100 105 110

cag acc tgt aca cag ctt cag gcc aca gca gag ccc agg tcc ccg agc 483
Gln Thr Cys Thr Gln Leu Gln Ala Thr Ala Glu Pro Arg Ser Pro Ser
115 120 125

cgc cgc ctc tcc cgc tgg ctg cac agg ctc cag gag gcc cag agc aag 531
Arg Arg Leu Ser Arg Trp Leu His Arg Leu Gln Glu Ala Gln Ser Lys
130 135 140

gag acc cct ggc tgc ctg gag gcc tct gtc acc tcc aac ctg ttt cgc 579
Glu Thr Pro Gly Cys Leu Glu Ala Ser Val Thr Ser Asn Leu Phe Arg
145 150 155

ctg ctc acc cgg gac ctc aag tgt gtg gcc aat gga gac cag tgt gtc 627
Leu Leu Thr Arg Asp Leu Lys Cys Val Ala Asn Gly Asp Gln Cys Val
160 165 170

tga cct 633

*

<210> 8
<211> 202
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(28)

<400> 8
Met Lys Pro Glu Thr Ala Gly Gly His Met Leu Leu Leu Leu Pro
-25 -20 -15
Leu Leu Leu Ala Ala Val Leu Thr Arg Thr Gln Ala Asp Pro Val Pro
-10 -5 1
Arg Ala Thr Arg Leu Pro Val Glu Ala Lys Asp Cys His Ile Ala Gln
5 10 15 20
Phe Lys Ser Leu Ser Pro Lys Glu Leu Gln Ala Phe Lys Lys Ala Lys
25 30 35
Asp Ala Ile Glu Lys Arg Leu Leu Glu Lys Asp Leu Arg Cys Ser Ser
40 45 50
His Leu Phe Pro Arg Ala Trp Asp Leu Lys Gln Leu Gln Val Gln Glu
55 60 65
Arg Pro Lys Ala Leu Gln Ala Glu Val Ala Leu Thr Leu Lys Val Trp
70 75 80
Glu Asn Met Thr Asp Ser Ala Leu Ala Thr Ile Leu Gly Gln Pro Leu
85 90 95 100
His Thr Leu Ser His Ile His Ser Gln Leu Gln Thr Cys Thr Gln Leu
105 110 115
Gln Ala Thr Ala Glu Pro Arg Ser Pro Ser Arg Arg Leu Ser Arg Trp
120 125 130
Leu His Arg Leu Gln Glu Ala Gln Ser Lys Glu Thr Pro Gly Cys Leu
135 140 145
Glu Ala Ser Val Thr Ser Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu
150 155 160
Lys Cys Val Ala Asn Gly Asp Gln Cys Val
165 170

<210> 9
<211> 632
<212> DNA
<213> Mus musculus

<220>
<221> sig_peptide
<222> (22)...(105)

<221> mat_peptide
<222> (106)...(630)

<221> CDS
<222> (22)...(630)

<400> 9
tcacagaccc cggagagcaa c atg aag cca gaa aca gct ggg ggc cac atg 51
Met Lys Pro Glu Thr Ala Gly Gly His Met
-25 -20

<210> 10
<211> 202
<212> PRT
<213> *Mus musculus*

<220>
<221> SIGNAL

<222> (1)...(28)

<400> 10
 Met Lys Pro Glu Thr Ala Gly Gly His Met Leu Leu Leu Leu Leu Pro
 -25 -20 -15
 Leu Leu Leu Ala Ala Val Leu Thr Arg Thr Gln Ala Asp Pro Val Pro
 -10 -5 1
 Arg Ala Thr Arg Leu Pro Val Glu Ala Lys Asp Cys His Ile Ala Gln
 5 10 15 20
 Phe Lys Ser Leu Ser Pro Lys Glu Leu Gln Ala Phe Lys Lys Ala Lys
 25 30 35
 Gly Ala Ile Glu Lys Arg Leu Leu Glu Lys Asp Met Arg Cys Ser Ser
 40 45 50
 His Leu Ile Ser Arg Ala Trp Asp Leu Lys Gln Leu Gln Val Gln Glu
 55 60 65
 Arg Pro Lys Ala Leu Gln Ala Glu Val Ala Leu Thr Leu Lys Val Trp
 70 75 80
 Glu Asn Ile Asn Asp Ser Ala Leu Thr Thr Ile Leu Gly Gln Pro Leu
 85 90 95 100
 His Thr Leu Ser His Ile His Ser Gln Leu Gln Thr Cys Thr Gln Leu
 105 110 115
 Gln Ala Thr Ala Glu Pro Lys Pro Pro Ser Arg Arg Leu Ser Arg Trp
 120 125 130
 Leu His Arg Leu Gln Glu Ala Gln Ser Lys Glu Thr Pro Gly Cys Leu
 135 140 145
 Glu Asp Ser Val Thr Ser Asn Leu Phe Gln Leu Leu Leu Arg Asp Leu
 150 155 160
 Lys Cys Val Ala Ser Gly Asp Gln Cys Val
 165 170

<210> 11
<211> 520
<212> PRT
<213> Homo sapiens

<400> 11
 Met Ala Gly Pro Glu Arg Trp Gly Pro Leu Leu Leu Cys Leu Leu Gln
 1 5 10 15
 Ala Ala Pro Gly Arg Pro Arg Leu Ala Pro Pro Gln Asn Val Thr Leu
 20 25 30
 Leu Ser Gln Asn Phe Ser Val Tyr Leu Thr Trp Leu Pro Gly Leu Gly
 35 40 45
 Asn Pro Gln Asp Val Thr Tyr Phe Val Ala Tyr Gln Ser Ser Pro Thr
 50 55 60
 Arg Arg Arg Trp Arg Glu Val Glu Glu Cys Ala Gly Thr Lys Glu Leu
 65 70 75 80
 Leu Cys Ser Met Met Cys Leu Lys Lys Gln Asp Leu Tyr Asn Lys Phe
 85 90 95
 Lys Gly Arg Val Arg Thr Val Ser Pro Ser Ser Lys Ser Pro Trp Val
 100 105 110
 Glu Ser Glu Tyr Leu Asp Tyr Leu Phe Glu Val Glu Pro Ala Pro Pro
 115 120 125
 Val Leu Val Leu Thr Gln Thr Glu Glu Ile Leu Ser Ala Asn Ala Thr
 130 135 140
 Tyr Gln Leu Pro Pro Cys Met Pro Pro Leu Asp Leu Lys Tyr Glu Val
 145 150 155 160
 Ala Phe Trp Lys Glu Gly Ala Gly Asn Lys Thr Leu Phe Pro Val Thr
 165 170 175
 Pro His Gly Gln Pro Val Gln Ile Thr Leu Gln Pro Ala Ala Ser Glu
 180 185 190

His His Cys Leu Ser Ala Arg Thr Ile Tyr Thr Phe Ser Val Pro Lys
 195 200 205
 Tyr Ser Lys Phe Ser Lys Pro Thr Cys Phe Leu Leu Glu Val Pro Glu
 210 215 220
 Ala Asn Trp Ala Phe Leu Val Leu Pro Ser Leu Leu Ile Leu Leu Leu
 225 230 235 240
 Val Ile Ala Ala Gly Gly Val Ile Trp Lys Thr Leu Met Gly Asn Pro
 245 250 255
 Trp Phe Gln Arg Ala Lys Met Pro Arg Ala Leu Asp Phe Ser Gly His
 260 265 270
 Thr His Pro Val Ala Thr Phe Gln Pro Ser Arg Pro Glu Ser Val Asn
 275 280 285
 Asp Leu Phe Leu Cys Pro Gln Lys Glu Leu Thr Arg Gly Val Arg Pro
 290 295 300
 Thr Pro Arg Val Arg Ala Pro Ala Thr Gln Gln Thr Arg Trp Lys Lys
 305 310 315 320
 Asp Leu Ala Glu Asp Glu Glu Glu Asp Glu Glu Asp Thr Glu Asp
 325 330 335
 Gly Val Ser Phe Gln Pro Tyr Ile Glu Pro Pro Ser Phe Leu Gly Gln
 340 345 350
 Glu His Gln Ala Pro Gly His Ser Glu Ala Gly Gly Val Asp Ser Gly
 355 360 365
 Arg Pro Arg Ala Pro Leu Val Pro Ser Glu Gly Ser Ser Ala Trp Asp
 370 375 380
 Ser Ser Asp Arg Ser Trp Ala Ser Thr Val Asp Ser Ser Trp Asp Arg
 385 390 395 400
 Ala Gly Ser Ser Gly Tyr Leu Ala Glu Lys Gly Pro Gly Gln Gly Pro
 405 410 415
 Gly Gly Asp Gly His Gln Glu Ser Leu Pro Pro Pro Glu Phe Ser Lys
 420 425 430
 Asp Ser Gly Phe Leu Glu Glu Leu Pro Glu Asp Asn Leu Ser Ser Trp
 435 440 445
 Ala Thr Trp Gly Thr Leu Pro Pro Glu Pro Asn Leu Val Pro Gly Gly
 450 455 460
 Pro Pro Val Ser Leu Gln Thr Leu Thr Phe Cys Trp Glu Ser Ser Pro
 465 470 475 480
 Glu Glu Glu Glu Ala Arg Glu Ser Glu Ile Glu Asp Ser Asp Ala
 485 490 495
 Gly Ser Trp Gly Ala Glu Ser Thr Gln Arg Thr Glu Asp Arg Gly Arg
 500 505 510
 Thr Leu Gly His Tyr Met Ala Arg
 515 520

<210> 12
 <211> 531
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> mature protein of SEQ ID NO: 1, with 3' Met added

<221> CDS
 <222> (1)...(531)

<400> 12
 atg gtt cct gtc gcc agg ctc cac ggg gct ctc ccg gat gca agg ggc 48
 Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15

tgc cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc 96

Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala			
20	25	30	
ttt aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac			144
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp			
35	40	45	
tgc agg tgc cac tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag			192
Cys Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln			
50	55	60	
ctg cag gtg agg gag cgc ccc atg gct ttg gag gct gag ctg gcc ctg			240
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu			
65	70	75	80
acg ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg gtg			288
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val			
85	90	95	
gac gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag			336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln			
100	105	110	
ttc cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg			384
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg			
115	120	125	
ggc cgc ctc cac cat tgg ctg tac cgg ctc cag gag gcc cca aaa aag			432
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys			
130	135	140	
gag tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc			480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg			
145	150	155	160
ctc ctc acg cga gac ctg aat tgt gtt gcc agt ggg gac ctg tgt gtc			528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val			
165	170	175	
tga			531
*			

<210> 13
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> mature protein of SEQ ID NO: 1, with 3' Met added

<400> 13
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
1 5 10 15
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
20 25 30
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
35 40 45
Cys Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
50 55 60

Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
 145 150 155 160
 Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 14
 <211> 621
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> mature protein of SEQ ID NO: 3, with 3' Met added

<221> CDS
 <222> (1)...(549)

<400> 14

atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc	48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys	
1 5 10 15	
cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc	96
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe	
20 25 30	
aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144
Lys Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp	
35 40 45	
agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu	
50 55 60	
cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr	
65 70 75 80	
ctg aag gtc ctg gag gcc gct gtc cca gcc ctg gag gac gtc cta	288
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu	
85 90 95	
gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc	336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala	
100 105 110	
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc	384
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu	
115 120 125	
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct	432

His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg		480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
cga gac ctc aaa tat gtg gcc gat ggg aac ctg tgt ctg aga acg tca		528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser		
165	170	175
acc cac cct gag tcc acc tga caccccacac cttatttatg cgctgagccc		579
Thr His Pro Glu Ser Thr *		
180		
tactccttcc ttaatttatt tcctctcacc ctttatttat ga		621
<210> 15		
<211> 182		
<212> PRT		
<213> Artificial Sequence		
<220>		
<223> mature protein of SEQ ID NO: 3, with 3' Met added		
<400> 15		
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys		
1	5	10
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe		15
20	25	30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp		
35	40	45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu		
50	55	60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr		
65	70	75
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu		80
85	90	95
Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala		
100	105	110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu		
115	120	125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser		160
165	170	175
Thr His Pro Glu Ser Thr		
180		
<210> 16		
<211> 531		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> mature protein of SEQ ID NO: 5, with 3' Met added		
<221> CDS		

<222> (1) . . . (531)

<400> 16	48
atg gtt cct gtc gcc agg ctc cgc ggg gct ctc ccg gat gca agg ggc	
Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly	
1 5 10 15	
tgc cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc	96
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala	
20 25 30	
ttt aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac	144
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp	
35 40 45	
tgc aag tgc cgc tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag	192
Cys Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln	
50 55 60	
ctg cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg	240
Ieu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu	
65 70 75 80	
acg ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg ggg	288
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly	
85 90 95	
gat gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag	336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	
100 105 110	
ctc cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg	384
Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg	
115 120 125	
ggc cgc ctc cac cat tgg ctg cac cgg ctc cag gag gcc cca aaa aag	432
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
gag tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc	480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
ctc ctc acg cga gac ctg aat tgt gtt gcc agc ggg gac ctg tgt gtc	528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	
tga	531
*	

<210> 17
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> mature protein of SEQ ID NO: 5, with 3' Met added

<400> 17

Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15
 Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
 20 25 30
 Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
 35 40 45
 Cys Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
 145 150 155 160
 Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 18
 <211> 528
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-28A mutant C48S

<221> CDS
 <222> (1)...(528)

<400> 18
 gtt cct gtc gcc agg ctc cac ggg gct ctc ccg gat gca agg ggc tgc 48
 Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly Cys
 1 5 10 15
 cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc ttt 96
 His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
 20 25 30
 aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac tcc 144
 Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp Ser
 35 40 45
 agg tgc cac tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag ctg 192
 Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu
 50 55 60
 cag gtg agg gag cgc ccc atg gct ttg gag gct gag ctg gcc ctg acg 240
 Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg gtg gac 288
 Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val Asp
 85 90 95
 gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag ttc 336

Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Phe	
100																110
cgg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cgg	ggc	384
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly	
115																125
cgc	ctc	cac	cat	tgg	ctg	tac	cgg	ctc	cag	gag	gcc	cca	aaa	aag	gag	432
Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	
130																140
tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	480
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	
145																160
ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agt	ggg	gac	ctg	tgt	gtc	tga	528
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	*	
165																175

<210> 19

<211> 175

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-28A mutant C48S

<400> 19

Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys	
1																15
His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe	
20																30
Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	Ser	
35																45
Arg	Cys	His	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	Leu	
50																60
Gln	Val	Arg	Glu	Arg	Pro	Met	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	
65																80
Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Val	Asp	
85																95
Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	Ile	Leu	Ser	Gln	Phe		
100																110
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly	
115																125
Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	
130																140
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	
145																160
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val		
165																175

<210> 20

<211> 531

<212> DNA

<213> Artificial Sequence

<220>

<223> met IL-28A mutant C49S

<221> CDS

<222> (1)...(531)

<400> 20

atg	gtt	cct	gtc	gcc	agg	ctc	cac	ggg	gct	ctc	ccg	gat	gca	agg	ggc	48
Met	Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	
1	5								10				15			

tgc	cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	96
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	
20								25					30			

ttt	aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	ctg	aag	gac	144
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	
35					40					45						

tcc	agg	tgc	cac	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	192
Ser	Arg	Cys	His	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	
50					55					60						

ctg	cag	gtg	agg	gag	cgc	ccc	atg	gct	ttg	gag	gct	gag	ctg	gcc	ctg	240
Leu	Gln	Val	Arg	Glu	Arg	Pro	Met	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	
65					70				75				80			

acg	ctg	aag	gtt	ctg	gag	gcc	acc	gct	gac	act	gac	cca	gcc	ctg	gtg	288
Thr	Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Val	
85					90					95						

gac	gtc	ttg	gac	cag	ccc	ctt	cac	acc	ctg	cac	cat	atc	ctc	tcc	cag	336
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	
100					105					110						

ttc	cg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cg	384
Phe	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	
115					120					125						

ggc	cgc	ctc	cac	cat	tgg	ctg	tac	cg	ctc	cag	gag	gcc	cca	aaa	aag	432
Gly	Arg	Ileu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	
130					135					140						

gag	tcc	cct	ggc	tgc	ctc	gag	gcc	tct	g	tc	acc	ttc	aac	ctc	ttc	480
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145					150					155			160			

ctc	ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agt	ggg	gac	ctg	tgt	gtc	528
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
165					170					175						

tga	*															531
-----	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	-----

<210> 21

<211> 176

<212> PRT

<213> Artificial Sequence

<220>

<223> met IL-28A mutant C49S

<400> 21

Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly			
1	5	10	15
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala			
20	25	30	
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp			
35	40	45	
Ser Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln			
50	55	60	
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu			
65	70	75	80
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val			
85	90	95	
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln			
100	105	110	
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg			
115	120	125	
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys			
130	135	140	
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg			
145	150	155	160
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val			
165	170	175	

<210> 22

<211> 528

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-28A mutant C50S

<221> CDS

<222> (1)...(528)

<400> 22

gtt cct gtc gcc agg ctc cac ggg gct ctc ccg gat gca agg ggc tgc	48
Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly Cys	
1	5
10	15

cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc ttt	96
His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe	
20	25
30	

aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac tgc	144
Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp Cys	
35	40
45	

agg tcc cac tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag ctg	192
Arg Ser His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu	
50	55
60	

cag gtg agg gag cgc ccc atg gct ttg gag gct gag ctg gcc ctg acg	240
Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu Thr	
65	70
75	80

ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg gtg gac	288
Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val Asp	
85	90
95	

gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag ttc	336
Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Phe	
100 105 110	
cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg ggc	384
Arg Ala Cys. Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly	
115 120 125	
cgc ctc cac cat tgg ctg tac cgg ctc cag gag gcc cca aaa aag gag	432
Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys Glu	
130 135 140	
tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc ctc	480
Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu	
145 150 155 160	
ctc acg cga gac ctg aat tgt gtt gcc agt ggg gac ctg tgt gtc tga	528
Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val *	
165 170 175	

<210> 23
 <211> 175
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-28A mutant C50S

<400> 23
 Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly Cys
 1 5 10 15
 His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
 20 25 30
 Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp Cys
 35 40 45
 Arg Ser His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val Asp
 85 90 95
 Val Leu Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Phe
 100 105 110
 Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly
 115 120 125
 Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys Glu
 130 135 140
 Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu
 145 150 155 160
 Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 24
 <211> 531
 <212> DNA
 <213> Artificial Sequence

<220>

<223> met IL-28A mutant C51S

<221> CDS

<222> (1)...(531)

<400> 24

atg	gtt	cct	gtc	gcc	agg	ctc	cac	ggg	gct	ctc	ccg	gat	gca	agg	ggc	48
Met	Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	
1			5						10				15			

tgc	cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	96
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	
20					25							30				

ttt	aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	ctg	aag	gac	144
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	
35					40							45				

tgc	agg	tcc	cac	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	192
Cys	Arg	Ser	His	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	
50					55					60						

ctg	cag	gtg	agg	gag	cgc	ccc	atg	gct	ttg	gag	gct	gag	ctg	gcc	ctg	240
Leu	Gln	Val	Arg	Glu	Arg	Pro	Met	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	
65					70					75			80			

acg	ctg	aag	gtt	ctg	gag	gcc	acc	gct	gac	act	gac	cca	gcc	ctg	gtg	288
Thr	Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Val	
85					90					95						

gac	gtc	ttg	gac	cag	ccc	ctt	cac	acc	ctg	cac	cat	atc	atc	ctc	tcc	336
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	
100					105					110						

ttc	cgg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cgg	384
Phe	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	
115					120					125						

ggc	cgc	ctc	cac	cat	tgg	ctg	tac	cg	ctc	cag	gag	gcc	cca	aaa	aag	432
Gly	Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	
130					135					140						

gag	tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	480
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145					150					155			160			

ctc	ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agt	ggg	gac	ctg	tgt	gtc	528
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
165					170					175						

tga																531
-----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	-----

*																
---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

<210> 25

<211> 176

<212> PRT

<213> Artificial Sequence

<220>

<223> met IL-28A mutant C51S

<400> 25

Met	Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly
1				5					10				15		
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala
				20				25				30			
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	
				35				40				45			
Cys	Arg	Ser	His	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln
				50				55				60			
Leu	Gln	Val	Arg	Glu	Arg	Pro	Met	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu
65					70				75				80		
Thr	Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Val
					85				90				95		
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln
				100				105				110			
Phe	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg
				115				120				125			
Gly	Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys
				130				135				140			
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg
145					150				155				160		
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val
					165				170				175		

<210> 26

<211> 546

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 mutant C171S

<221> CDS

<222> (1)...(546)

<400> 26

ggt	ccg	gtt	ccg	acc	tct	aaa	cca	acc	acc	act	ggt	aaa	ggt	tgc	cac
Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly	Lys	Gly	Cys	His	
1				5				10				15			

atc	ggt	cgt	ttc	aaa	tct	ctg	tct	ccg	cag	gaa	ctg	gct	tct	ttc	aaa
Ile	Gly	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	Lys
					20				25				30		

aaa	gct	cgt	gac	gct	ctg	gaa	tct	ctg	aaa	ctg	aaa	aac	tgg	tct	
Lys	Ala	Arg	Asp	Ala	Leu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	Ser	
					35				40			45			

tgc	tct	tct	ccg	gtt	ttc	ccg	ggt	aac	tgg	gat	ctg	cgt	ctg	ctg	cag
Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu	Gln
					50				55			60			

gtt	cgt	gaa	cgt	ccg	gtt	gct	ctg	gaa	gct	ctg	acc	ctg			240
Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	Leu
					65				70			75			80

aaa	gtt	ctg	gaa	gct	gca	ggt	cct	gct	ctg	gaa	gat	gtt	ctg	gat	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--

Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp		
85	90	95
cag ccg ctg cac act ctg cac cac atc ctg tct cag ctg cag gct tgc 336		
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys		
100	105	110
att caa ccg caa ccg acc gct ggt ccg cgt cgt ggt cgt ctg cac 384		
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His		
115	120	125
cac tgg ctg cat cgt ctg cag gaa gct ccg aaa aaa gaa tct gct ggt 432		
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly		
130	135	140
tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt ctg ctg acc cgt 480		
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg		
145	150	155
gat ctg aaa tac gtt gct gat ggt aac ctg tct ctg cgt acc tct acc 528		
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Ser Leu Arg Thr Ser Thr		
165	170	175
cat ccg gaa tct acc taa 546		
His Pro Glu Ser Thr *		
180		

<210> 27
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-29 mutant C171S

<400> 27			
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His			
1	5	10	15
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys			
20	25	30	
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser			
35	40	45	
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln			
50	55	60	
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu			
65	70	75	80
Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp			
85	90	95	
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys			
100	105	110	
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His			
115	120	125	
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly			
130	135	140	
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg			
145	150	155	160
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Ser Leu Arg Thr Ser Thr			
165	170	175	
His Pro Glu Ser Thr			
180			

<210> 28
 <211> 549
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> met IL-29 mutant C172S

 <221> CDS
 <222> (1)...(549)

 <400> 28
 atg ggt ccg gtt ccg acc tct aaa cca acc acc act ggt aaa ggt tgc 48
 Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
 1 5 10 15

 cac atc ggt cgt ttc aaa tct ctg tct ccg cag gaa ctg gct tct ttc 96
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30

 aaa aaa gct cgt gac gct ctg gaa gaa tct ctg aaa ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

 tct tgc tct tct ccg gtt ttc ccg ggt aac tgg gat ctg cgt ctg ctg 192
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60

 cag gtt cgt gaa cgt ccg gtt gct ctg gaa gct gaa ctg gct ctg acc 240
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80

 ctg aaa gtt ctg gaa gct gca ggt cct gct ctg gaa gat gtt ctg 288
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95

 gat cag ccg ctg cac act ctg cac atc atc ctg tct cag ctg cag gct 336
 Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
 100 105 110

 tgc att caa ccg caa ccg acc gct ggt ccg cgt ccg cgt ggt cgt ctg 384
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125

 cac cac tgg ctg cat cgt ctg cag gaa gct ccg aaa aaa gaa tct gct 432
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140

 ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt ctg ctg acc 480
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160

 cgt gat ctg aaa tac gtt gct gat ggt aac ctg tct ctg cgt acc tct 528
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Ser Leu Arg Thr Ser
 165 170 175

 acc cat ccg gaa tct acc taa 549
 Thr His Pro Glu Ser Thr *
 180

<210> 29
<211> 182

<212> PRT
<213> Artificial Sequence

<220>
<223> met IL-29 mutant C172S

<400> 29
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95
Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
100 105 110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
115 120 125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
130 135 140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
145 150 155 160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Ser Leu Arg Thr Ser
165 170 175
Thr His Pro Glu Ser Thr
180

<210> 30
<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 18

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 30
gtnccngtng cnmgnytnc a yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttyaarwsny tnwsnccnca rgarytncar gcnttyaarm gngcnaarga ygcnytngar 120
garwsnytny tnytnaarga ywsnmgnsty caywsnmgnsty tnttyccnmg nacntggay 180
ytnmgncary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytncaya cnytncayca yathytwnsn carttymngn cntgyathca rccncarccn 360
acngcnggnc cnmgnacnmg nggnmgnsty caycaytgg yntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytngar gcnwsgntna cnttyaayt ntymgnyt 480
ytnacnmngn ayytnaaytg ygtngcnwsn gngaytnt gygt 525

<210> 31

<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 20

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 31
gtncnctng cnmgnynca yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttyaarwsny tnwsncnca rgarytnkar gcnttyaarm gngcnaarga ygcnytngar 120
garwsnytny tnytnaarga ywsnmgnsty caywsnmgnsty nttyccnmg nacntggay 180
ytnmgnrcary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytncaya cnytncayca yathytnwsn carttymgng cntgyathca rccncarccn 360
acngcnggnc cnmgnacnmg nggnmgnsty caycaytggg tntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytnkar gcnwsngtna cnttyaayyt ntymgnsty 480
ytnacnmngng ayytnaaytg ygtngcnwsn ggngayytnt gygtnt 525

<210> 32
<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 22

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 32
gtncnctng cnmgnynca yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttyaarwsny tnwsncnca rgarytnkar gcnttyaarm gngcnaarga ygcnytngar 120
garwsnytny tnytnaarga ywsnmgnsty caywsnmgnsty nttyccnmg nacntggay 180
ytnmgnrcary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytncaya cnytncayca yathytnwsn carttymgng cntgyathca rccncarccn 360
acngcnggnc cnmgnacnmg nggnmgnsty caycaytggg tntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytnkar gcnwsngtna cnttyaayyt ntymgnsty 480
ytnacnmngng ayytnaaytg ygtngcnwsn ggngayytnt gygtnt 525

<210> 33
<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 24

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 33
gtncnctng cnmgnynca yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttyaarwsny tnwsncnca rgarytnkar gcnttyaarm gngcnaarga ygcnytngar 120
garwsnytny tnytnaarga ywsnmgnsty caywsnmgnsty nttyccnmg nacntggay 180

ytnmgncary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytnacaya cnytnacaya yathytnwsn carttymngn cntgyathca rccncarccn 360
acngcnggnc cnmgnaacnmg nggnmgnyn caycaytgg tntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytngar gcnwsngtta cnttyaayyt ntymgnyn 480
ytnacnmngng ayytnaaytg ygtngcnwsn ggngayytnt gygtnt 525

<210> 34
<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 26

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 34
gtncnctng cnmgnynca yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttnaarwsny tnwsnccnca rgarytnacn gcnttyaarm gngcnaarga ygcnytnag 120
garwsnytny tnytnaarga ywsnmgntgy caywsnmgny tnttyccnmg nacntggay 180
ytnmgncary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytnacaya cnytnacaya yathytnwsn carttymngn cntgyathca rccncarccn 360
acngcnggnc cnmgnaacnmg nggnmgnyn caycaytgg tntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytngar gcnwsngtta cnttyaayyt ntymgnyn 480
ytnacnmngng ayytnaaytg ygtngcnwsn ggngayytnt gygtnt 525

<210> 35
<211> 525
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate sequence of SEQ ID NO: 28

<221> misc_feature
<222> (1)...(525)
<223> n = A,T,C or G

<400> 35
gtncnctng cnmgnynca yggngcnytn ccngaygcnm gnggntgyca yathgcncar 60
ttnaarwsny tnwsnccnca rgarytnacn gcnttyaarm gngcnaarga ygcnytnag 120
garwsnytny tnytnaarga ywsnmgntgy caywsnmgny tnttyccnmg nacntggay 180
ytnmgncary tncargtnmg ngarmgnccn atggcnytng argcngaryt ngcnytnacn 240
ytnaargtny tngargcnac ngcngayacn gayccngcny tngtngaygt nytngaycar 300
ccnytnacaya cnytnacaya yathytnwsn carttymngn cntgyathca rccncarccn 360
acngcnggnc cnmgnaacnmg nggnmgnyn caycaytgg tntaymgnyt ncargargcn 420
ccnaaraarg arwsnccnng ntgyytngar gcnwsngtta cnttyaayyt ntymgnyn 480
ytnacnmngng ayytnaaytg ygtngcnwsn ggngayytnt gygtnt 525

<210> 36
<211> 175
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-28A mutant C48X

```
<221> VARIANT
<222> (48)...(48)
<223> Xaa = Ser, Ala, Thr, Val or Asn
```

<400> 36
 Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly Cys
 1 5 10 15
 His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
 20 25 30
 Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp Xaa
 35 40 45
 Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val Asp
 85 90 95
 Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Phe
 100 105 110
 Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly
 115 120 125
 Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys Glu
 130 135 140
 Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu
 145 150 155 160
 Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 37
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> met IL-28A mutant C49X

<221> VARIANT
<222> (49)...(49)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 37
 Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15
 Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
 20 25 30
 Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
 35 40 45
 Xaa Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg

145	150	155	160
Leu	Leu	Thr	Arg
Asp	Leu	Asn	Cys
165	170		Val
		Ser	Gly
		Asp	Leu
		Cys	Val
			175

<210> 38
 <211> 175
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-28A mutant C50X

<221> VARIANT
 <222> (50)...(50)
 <223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 38

Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys
1					5				10				15		
His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe
	20					25						30			
Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	Cys	
	35					40						45			
Arg	Xaa	His	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	Leu
	50					55						60			
Gln	Val	Arg	Glu	Arg	Pro	Met	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr
	65					70					75			80	
Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Val	Asp
	85					90					95				
Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	Ile	Leu	Ser	Gln	Phe	
	100					105					110				
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly
	115					120					125				
Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu
	130					135					140				
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu
	145					150					155			160	
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
	165					170					175				

<210> 39
 <211> 176
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> met IL-28A mutant C51X

<221> VARIANT
 <222> (51)...(51)
 <223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 39

Met	Val	Pro	Val	Ala	Arg	Leu	His	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly
1						5				10				15	
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala
	20						25					30			
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	
	35						40					45			

Cys Arg Xaa His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
 145 150 155 160
 Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 40
<211> 181
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-29 mutant C171X

<221> VARIANT
<222> (171)...(171)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 40
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His
 1 5 10 15
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 41
<211> 182
<212> PRT
<213> Artificial Sequence

<220>

<223> met IL-29 mutant C172X

<221> VARIANT

<222> (172)...(172)

<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 41

Met	Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Thr	Gly	Lys	Gly	Cys
1															15
His	Ile	Gly	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe
	20														30
Lys	Lys	Ala	Arg	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp
	35														45
Ser	Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu
	50														60
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr
	65														80
Leu	Lys	Val	Leu	Glu	Ala	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu
	85														95
Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala
	100														110
Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu
	115														125
His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala
	130														140
Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr
	145														160
Arg	Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Xaa	Leu	Arg	Thr	Ser
	165														175
Thr	His	Pro	Glu	Ser	Thr										
	180														

<210> 42

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC40923

<400> 42

tccagggaat tcatataggc cggccaccat gaaactagac atgactggg

49

<210> 43

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC43152

<400> 43

ggggtgtggta caaccccaga gctgttttaa ggcgcgcctc tagactattt ttagacacac 60
aggccccac tggc

74

<210> 44

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC29740

<400> 44

ttgacaat^{ta} atcatcg^{gg}ct cgtataat^{gt} gtggaaatt^{gt} gagcggataa

50

<210> 45

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC29741

<400> 45

tctgatt^{aa} tctgtat^{ca} gctgaaaat^c ttatctcat^c cg

42

<210> 46

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC29736

<400> 46

gtggaaatt^{gt} gagcggataa caatttcaca cagaattcat taaagaggag aaattaact^c 60
cc

62

<210> 47

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC29738

<400> 47

gctgaaaat^c ttatctcat^c cgccaaaaca cccggagtt aatttctcct ctttaat^{gaa} 60
ttc

63

<210> 48

<211> 78

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44566

<400> 48

tcttccagag cgtcacgagc tttttgaaa gaagccagtt cctgcggaga cagagatt^g 60
aaacgaccga tgtggcaa

78

<210> 49

<211> 84

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44565

<400> 49
tcgtgacgct ctggaagaat ctctgaaact gaaaaactgg tcttgctctt ctccggttt 60
cccggttaac tgggatctgc gtct 84

<210> 50
<211> 71
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44564

<400> 50
aacagaagct tccaggcaac cagcagattc tttttcgga gtttcctgca gacgatgcag 60
ccagtgtgc a 71

<210> 51
<211> 73
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44563

<400> 51
aactggctct gaccctgaaa gttctggaag ctgctgcagg tcctgctctg gaagatgttc 60
tggatcagcc gct 73

<210> 52
<211> 74
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44562

<400> 52
tcagggtcag agccagttca gttccagag caaccggacg ttcacgaacc tgcagcagac 60
gcagatccca gtta 74

<210> 53
<211> 76
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44561

<400> 53
tcagctgcag gttgcattc aaccgcaacc gaccgctggt ccgcgtccgc gtggcgtct 60
gcaccactgg ctgcat 76

<210> 54
<211> 60
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC44560

<400> 54
atgcaaggct gcagctgaga caggatgtgg tgcagagtgt gcagcggctg atccagaaca 60

<210> 55
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44559

<400> 55
atgggtccgg ttccgacctc taaaccaacc accactggta aagggtgccatcg 60
tt 62

<210> 56
<211> 65
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44558

<400> 56
tttaggtatat tccggatggg tagaggtacg caggcacagg ttaccatcatc 60
cagat 65

<210> 57
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44557

<400> 57
tgcctggaaat cttctgttac cttcaacctg ttccgtctgc tgaccggta tctgaaatac 60
gttgctgat 69

<210> 58
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44340

<400> 58
cggtgctgat ggtaacctgt ctctgcgtac ctctacccat c 41

<210> 59
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44341

<400> 59

gatgggtaga ggtacgcaga gacagggtac catcagcaac g 41

<210> 60
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC41212

<400> 60
ctagaaataa ttttgttaa cttaagaag gagatata tatggccct gtccccactt 60
ccaagccc 68

<210> 61
<211> 67
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC41041

<400> 61
tctgtatcatc gctaaaaatc ttatctcatc cgccaaaaca ttaggtggac tcagggtggg 60
ttgacgt 67

<210> 62
<211> 65
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC43431

<400> 62
ctagaaataa ttttgttaa cttaagaag gagatata tatggccct gtcgccaggc 60
tccac 65

<210> 63
<211> 67
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC43437

<400> 63
taatctgtat caggctgaaa atcttatctc atccgc当地 acatcagaca cacaggtccc 60
cactggc 67

<210> 64
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44327

<400> 64
gtggccgatg ggaacctgtc cctgagaacg tcaacccac 39

<210> 65
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC44328

<400> 65
gtgggttgac gttctcaggg acaggttccc atcgccac 39

<210> 66
<211> 83
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide primer ZC45399

<400> 66
tcaggtccca ggtcctgggg aagaggcggg agtggcacct ggagtccttc agcagaagcg 60
actcttctaa ggcatcttg gcc 83

<210> 67
<211> 531
<212> DNA
<213> Artificial Sequence

<220>
<223> zcyto20 mature start from pYEL7b

<221> CDS
<222> (1)...(531)

<400> 67
atg gtt cct gtc gcc agg ctc cac ggg gct ctc ccg gat gca agg ggc 48
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
1 5 10 15

tgc cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc 96
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
20 25 30

ttt aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac 144
Phe Lys Arg Ala Lys Asp Ala Leu Glu Ser Leu Leu Leu Lys Asp
35 40 45

tgc agg tgc cac tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag 192
Cys Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
50 55 60

ctg cag gtg agg gag cgc ccc atg gct ttg gag gct gag ctg gcc ctg 240
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu
65 70 75 80

acg ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg gtg 288
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val
85 90 95

gac gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag 336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln

100	105	110	
ttc	cg	g	384
cgg	gcc	tgt	
atc	cag	cct	
cag	ccc	cag	
gca	ggg	ccc	
agg	ccc	agg	
acc	agg	acc	
cg	cc	cc	
Phe	Arg	Ala	
Ala	Cys	Ile	
Gln	Pro	Gln	
Pro	Thr	Pro	
Thr	Ala	Gly	
Ala	Gly	Pro	
Gly	Pro	Arg	
Arg	Thr	Arg	
	115	120	125
ggc	cgc	ctc	432
cac	cat	tgg	
tgc	ctg	tac	
cgg	ctc	cag	
gag	gcc	cca	
gag	gcc	aaa	
g	cc	aag	
Gly	Arg	Leu	
His	His	Trp	
Leu	Tyr	Arg	
Gln	Leu	Gln	
Glu	Ala	Pro	
Ala	Pro	Lys	
	130	135	140
gag	tcc	cct	480
ggc	tgc	ctc	
c	g	g	
ttc	acc	ttc	
tct	acc	ttc	
gtc	ttc	cgc	
Leu	Ser	Pro	
Gly	Cys	Gly	
Leu	Glu	Ala	
Glu	Ala	Ser	
Ala	Ser	Val	
Ser	Val	Thr	
Val	Thr	Phe	
	145	150	155
ctc	ctc	acg	528
cga	gac	ctg	
gac	aat	tgt	
ctg	tgt	gtt	
gcc	gtt	gcc	
agt	gcc	agt	
ggg	acc	ggg	
gac	ctc	gac	
ctg	tgt	ctg	
tgt	gtc	tgt	
gtc	gtc	gtc	
Leu	Leu	Thr	
Thr	Arg	Asp	
Asp	Leu	Asn	
Leu	Cys	Val	
Asn	Val	Ala	
Cys	Ala	Ser	
Val	Ser	Gly	
	165	170	175
tga			531
*			

<210> 68

<211> 83

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC45398

<400> 68

ggccaaagat	gccttagaag	agtcgcttct	gctgaaggac	tccaggtgcc	actccgcct	60
cttccccagg	acctgggacc	tga				83

<210> 69

<211> 83

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC45397

<400> 69

gctgcctcag	gtcccagg	tcgggaaaga	ggcgggagtg	ggacctgcag	tccttgcagca	60
gaagcgactc	ttcttgc	ttcttgc				83

<210> 70

<211> 83

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide primer ZC45396

<400> 70

agatgcctta	gaagagtcgc	ttctgctgaa	ggactgcagg	tcccactccc	gccttccc	60
caggacctgg	gacctgaggc	agc				83

<210> 71

<211> 1013

<212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (14) ... (991)

<400> 71

ccagcgtccg	tcc	atg	gcg	tgg	agc	ctt	ggg	agc	tgg	ctg	ggt	ggc	tgc	49		
Met	Ala	Trp	Ser	Leu	Gly	Ser	Trp	Leu	Gly	Gly	Cys					
1	5	10														
ctg	ctg	gtg	tca	gca	ttg	gga	atg	gta	cca	cct	ccc	gaa	aat	gtc	aga	97
Leu	Leu	Val	Ser	Ala	Leu	Gly	Met	Val	Pro	Pro	Pro	Glu	Asn	Val	Arg	
15	20	25														
atg	aat	tct	gtt	aat	ttc	aag	aac	att	cta	cag	tgg	gag	tca	cct	gct	145
Met	Asn	Ser	Val	Asn	Phe	Lys	Asn	Ile	Leu	Gln	Trp	Glu	Ser	Pro	Ala	
30	35	40														
ttt	gcc	aaa	ggg	aac	ctg	act	ttc	aca	gct	cag	tac	cta	agt	tat	agg	193
Phe	Ala	Lys	Gly	Asn	Leu	Thr	Phe	Thr	Ala	Gln	Tyr	Leu	Ser	Tyr	Arg	
45	50	55														
ata	ttc	caa	gat	aaa	tgc	atg	aat	act	acc	ttg	acg	gaa	tgt	gat	ttc	241
Ile	Phe	Gln	Asp	Lys	Cys	Met	Asn	Thr	Thr	Leu	Thr	Glu	Cys	Asp	Phe	
65	70	75														
tca	agt	ctt	tcc	aag	tat	ggt	gac	cac	acc	ttg	aga	gtc	agg	gct	gaa	289
Ser	Ser	Leu	Ser	Lys	Tyr	Gly	Asp	His	Thr	Leu	Arg	Val	Arg	Ala	Glu	
80	85	90														
ttt	gca	gat	gag	cat	tca	gac	tgg	gta	aac	atc	acc	ttc	tgt	cct	gtg	337
Phe	Ala	Asp	Glu	His	Ser	Asp	Trp	Val	Asn	Ile	Thr	Phe	Cys	Pro	Val	
95	100	105														
gat	gac	acc	att	att	gga	ccc	cct	gga	atg	caa	gta	gaa	gta	ctt	gct	385
Asp	Asp	Thr	Ile	Ile	Gly	Pro	Pro	Gly	Met	Gln	Val	Glu	Val	Leu	Ala	
110	115	120														
gat	tct	tta	cat	atg	cgt	ttc	tta	gcc	cct	aaa	att	gag	aat	gaa	tac	433
Asp	Ser	Leu	His	Met	Arg	Phe	Leu	Ala	Pro	Lys	Ile	Glu	Asn	Glu	Tyr	
125	130	135														
gaa	act	tgg	act	atg	aag	aat	gtg	tat	aac	tca	tgg	act	tat	aat	gtg	481
Glu	Thr	Trp	Thr	Met	Lys	Asn	Val	Tyr	Asn	Ser	Trp	Thr	Tyr	Asn	Val	
145	150	155														
caa	tac	tgg	aaa	aac	ggt	act	gat	gaa	aag	ttt	caa	att	act	ccc	cag	529
Gln	Tyr	Trp	Lys	Asn	Gly	Thr	Asp	Glu	Lys	Phe	Gln	Ile	Thr	Pro	Gln	
160	165	170														
tat	gac	ttt	gag	gtc	ctc	aga	aac	ctg	gag	cca	tgg	aca	act	tat	tgt	577
Tyr	Asp	Phe	Glu	Val	Leu	Arg	Asn	Leu	Glu	Pro	Trp	Thr	Thr	Tyr	Cys	
175	180	185														
gtt	caa	gtt	cga	ggg	ttt	ctt	cct	gat	cg	aaa	gct	ggg	gaa	tgg	625	
Val	Gln	Val	Arg	Gly	Phe	Leu	Pro	Asp	Arg	Asn	Lys	Ala	Gly	Glu	Trp	
190	195	200														
agt	gag	cct	gtc	tgt	gag	caa	aca	acc	cat	gac	gaa	acg	gtc	ccc	tcc	673

Ser	Glu	Pro	Val	Cys	Glu	Gln	Thr	Thr	His	Asp	Glu	Thr	Val	Pro	Ser	
205					210				215					220		
tgg atg gtg gcc gtc atc ctc atg gcc tcg gtc ttc atg gtc tgc ctg															721	
Trp	Met	Val	Ala	Val	Ile	Leu	Met	Ala	Ser	Val	Phe	Met	Val	Cys	Leu	
					225				230				235			
gca ctc ctc ggc tgc ttc tcc ttg ctg tgg tgc gtt tac aag aag aca															769	
Ala	Leu	Leu	Gly	Cys	Phe	Ser	Leu	Leu	Trp	Cys	Val	Tyr	Lys	Lys	Thr	
					240				245			250				
aag tac gcc ttc tcc cct agg aat tct ctt cca cag cac ctg aaa gag															817	
Lys	Tyr	Ala	Phe	Ser	Pro	Arg	Asn	Ser	Leu	Pro	Gln	His	Leu	Lys	Glu	
					255				260			265				
ttt ttg ggc cat cct cat cat aac aca ctt ctg ttt ttc tcc ttt cca															865	
Phe	Leu	Gly	His	Pro	His	Asn	Thr	Leu	Leu	Phe	Phe	Ser	Phe	Pro		
					270				275			280				
ttg tcg gat gag aat gat gtt ttt gac aag cta agt gtc att gca gaa															913	
Leu	Ser	Asp	Glu	Asn	Asp	Val	Phe	Asp	Lys	Leu	Ser	Val	Ile	Ala	Glu	
					285				290			295			300	
gac tct gag agc ggc aag cag aat cct ggt gac agc tgc agc ctc ggg															961	
Asp	Ser	Glu	Ser	Gly	Lys	Gln	Asn	Pro	Gly	Asp	Ser	Cys	Ser	Leu	Gly	
					305				310			315				
acc ccg cct ggg cag ggg ccc caa agc tag gctctgagaa ggaaacacac															1011	
Thr	Pro	Pro	Gly	Gln	Gly	Pro	Gln	Ser	*							
					320				325							
tc															1013	
<210> 72																
<211> 49																
<212> DNA																
<213> Artificial Sequence																
<220>																
<223> oligonucleotide primer ZC40922																
<400> 72																
tccagggaat tcatataggc cggccaccat ggctgcagct tggaccgtg															49	
<210> 73																
<211> 71																
<212> DNA																
<213> Artificial Sequence																
<220>																
<223> oligonucleotide primer ZC43153																
<400> 73																
gggggtgggta caaccccaaga gctgtttaa ggcgcgcctc tagactattt ttaggtggac															60	
tcagggtggg t															71	
<210> 74																
<211> 546																
<212> DNA																
<213> Artificial Sequence																

<220>

<223> IL29 mutant C15X, Asn169

<221> CDS

<222> (1)...(546)

<221> variation

<222> (44)...(45)

<223> n = A, G, T, or C

<400> 74

ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His	
1 5 10 15	

att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20 25 30	

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35 40 45	

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50 55 60	

gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	

aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	

cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	

atc cag cct cag ccc aca gca ggg ccc agg ccc cggt ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	

cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	

tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	

gac ctc aaa tat gtg gcc gat ggg aay ctg tgt ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr	
165 170 175	

cac cct gag tcc acc tga	546
His Pro Glu Ser Thr *	
180	

<210> 75

<211> 181
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (15)...(15)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> IL29 mutant C15X, Asn169

<400> 75
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
1 5 10 15
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
20 25 30
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
35 40 45
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
50 55 60
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
65 70 75 80
Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
85 90 95
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
100 105 110
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
115 120 125
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
130 135 140
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
145 150 155 160
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr
165 170 175
His Pro Glu Ser Thr
180

<210> 76
<211> 549
<212> DNA
<213> Artificial Sequence

<220>
<223> Met IL29 mutant C16X, Asn170

<221> CDS
<222> (1)...(549)

<221> variation
<222> (47)...(48)
<223> n = A, T, G, or C

<400> 76
atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn 48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
1 5 10 15

cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144		
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp			
35	40	45	
agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192		
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu			
50	55	60	
cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240		
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80
ctg aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta	288		
Leu Lys Val Leu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu			
85	90	95	
gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc	336		
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc	384		
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct	432		
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg	480		
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
cga gac ctc aaa tat gtg gcc gat ggg aay ctg tgt ctg aga acg tca	528		
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser			
165	170	175	
acc cac cct gag tcc acc tga	549		
Thr His Pro Glu Ser Thr *			
180			

<210> 77
<211> 182
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (16)...(16)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> Met IL29 mutant C16X, Asn170

<400> 77
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45

Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95
 Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
 100 105 110
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser
 165 170 175
 Thr His Pro Glu Ser Thr
 180

<210> 78
 <211> 546
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL29 mutant C15X, Asp169

<221> CDS
 <222> (1)...(546)

<221> variation
 <222> (44)...(45)
 <223> n = A, T, G, or C

<400> 78
 ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn cac 48
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
 1 5 10 15
 att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag 96
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt 144
 Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag 192
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg 240
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac 288
 Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt 336

Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys		
100	105	110
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384	
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His		
115	120	125
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432	
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly		
130	135	140
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480	
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg		
145	150	155
gac ctc aaa tat gtg gcc gat ggg gay ctg tgt ctg aga acg tca acc	528	
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr		
165	170	175
cac cct gag tcc acc tga	546	
His Pro Glu Ser Thr *		
180		

<210> 79
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant C15X, Asp169

<221> VARIANT
 <222> (15)...(15)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 79
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
 1 5 10 15
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 80
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant C16X, Asp170

<221> CDS
 <222> (1)...(549)

<221> variation
 <222> (47)...(48)
 <223> n = A, T, G, or C

<400> 80
 atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn 48
 Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
 1 5 10 15

cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc 192
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60

cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg 240
 Gln Val Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80

ctg aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta 288
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95

gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc 336
 Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
 100 105 110

tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc 384
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125

cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct 432
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140

ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg 480
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160

cga gac ctc aaa tat gtg gcc gat ggg gay ctg tgt ctg aga acg tca 528
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser
 165 170 175

acc cac cct gag tcc acc tga
Thr His Pro Glu Ser Thr *
180

549

<210> 81

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Met IL29 mutant C16X, Asp170

<221> VARIANT

<222> (16)...(16)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 81

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95
Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
100 105 110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
115 120 125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
130 135 140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
145 150 155 160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser
165 170 175
Thr His Pro Glu Ser Thr
180

<210> 82

<211> 546

<212> DNA

<213> Artificial Sequence

<220>

<223> IL29 mutant Asp169, C171X

<221> CDS

<222> (1)...(546)

<221> variation

<222> (512)...(513)

<223> n = A, T, G, or C

<400> 82

ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His	
1 5 10 15	
att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20 25 30	
aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35 40 45	
tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50 55 60	
gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	
aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	
gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr	
165 170 175	
cac cct gag tcc acc tga	546
His Pro Glu Ser Thr *	
180	

<210> 83
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant Asp169, C171X

<221> VARIANT
 <222> (171)...(171)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 83

Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His
 1 5 10 15
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 84
<211> 549
<212> DNA
<213> Artificial Sequence

<220>
<223> Met IL29 mutant Asp170, C172X

<221> CDS
<222> (1)...(549)

<221> variation
<222> (515)...(516)
<223> n = A, T, G, or C

<400> 84

atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc	48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys	
1 5 10 15	
cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc	96
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe	
20 25 30	
aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp	
35 40 45	
agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu	
50 55 60	
cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr	

65	70	75	80	
ctg aag gtc ctg gag gcc gct gtc cca gcc ctg gag gac gtc cta				288
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu				
85	90	95		
gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc				336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala				
100	105	110		
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc				384
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu				
115	120	125		
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct				432
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala				
130	135	140		
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg				480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr				
145	150	155	160	
cga gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca				528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser				
165	170	175		
acc cac cct gag tcc acc tga				549
Thr His Pro Glu Ser Thr *				
180				

<210> 85

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Met IL29 mutant Asp170, C172X

<221> VARIANT

<222> (172)...(172)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 85

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys				
1	5	10	15	
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe				
20	25	30		
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp				
35	40	45		
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu				
50	55	60		
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr				
65	70	75	80	
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu				
85	90	95		
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala				
100	105	110		
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu				
115	120	125		
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala				

130	135	140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser		
165	170	175
Thr His Pro Glu Ser Thr		
180		

<210> 86
 <211> 546
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL29 mutant T10P, Asn169, C171X
 <221> CDS
 <222> (1)...(546)

<221> variation
 <222> (512)...(513)
 <223> n = A, T, G, or C

<400> 86
 ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc tgc cac 48
 Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys His
 1 5 10 15

att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag 96
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt 144
 Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag 192
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60

gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg 240
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80

aag gtc ctg gag gcc gct gtc cca gcc ctg gag gac gtc cta gac 288
 Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95

cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt 336
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110

atc cag cct cag ccc aca gca ggg ccc agg ccc cggt ggc cgc ctc cac 384
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125

cac tgg ctg cac cggt ctc cag gag gcc ccc aaa aag gag tcc gct ggc 432
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140

tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga 480
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160

gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca acc 528
 Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr
 165 170 175

cac cct gag tcc acc tga 546
 His Pro Glu Ser Thr *
 180

<210> 87
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant T10P, Asn169, C171X

<221> VARIANT
 <222> (171)...(171)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 87
 Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys His
 1 5 10 15
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 88
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant T11P, Asn170, C172X

<221> CDS

<222> (1)...(549)

<221> variation

<222> (515)...(516)

<223> n = A, T, G, or C

<400> 88

atg ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc tgc 48

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys
1 5 10 15cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg 144
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc 192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg 240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80ctg aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta 288
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc 336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
100 105 110tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc 384
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
115 120 125cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct 432
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
130 135 140ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg 480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
145 150 155 160cga gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca 528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser
165 170 175acc cac cct gag tcc acc tga 549
Thr His Pro Glu Ser Thr *
180

<210> 89

<211> 182

<212> PRT

<213> Artificial Sequence

<220>
<223> Met IL29 mutant T11P, Asn170, C172X

<221> VARIANT
<222> (172)...(172)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 89
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95
Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
100 105 110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
115 120 125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
130 135 140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
145 150 155 160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser
165 170 175
Thr His Pro Glu Ser Thr
180

<210> 90
<211> 546
<212> DNA
<213> Artificial Sequence

<220>
<223> IL29 mutant T10P, C15X, Asn169

<221> CDS
<222> (1)...(546)

<221> variation
<222> 30, 44, 45
<223> n = A, T, G, or C

<400> 90
ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc dnn cac 48
Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa His
1 5 10 15

att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag 96
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
20 25 30

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt 144
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
35 40 45

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50 55 60	
gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	
aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	
gac ctc aaa tat gtg gcc gat ggg aay ctg tgt ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr	
165 170 175	
cac cct gag tcc acc tga	546
His Pro Glu Ser Thr *	
180	

<210> 91
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant T10P, C15X, Asn169

<221> VARIANT
 <222> (15)...(15)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 91
 Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa His
 1 5 10 15
 Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80

Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 92
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant T11P, C16X, Asn170

<221> CDS
 <222> (1)...(549)

<221> variation
 <222> 33, 47, 48
 <223> n = A, T, G, or C

<400> 92

atg ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc dnn	48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa	
1 5 10 15	
cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc	96
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe	
20 25 30	
aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144
Lys Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp	
35 40 45	
agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu	
50 55 60	
cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr	
65 70 75 80	
ctg aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta	288
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu	
85 90 95	
gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc	336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala	
100 105 110	
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc	384

Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu		
115	120	125
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct		432
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg		480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
cga gac ctc aaa tat gtg gcc gat ggg aay ctg tgt ctg aga acg tca		528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser		
165	170	175
acc cac cct gag tcc acc tga		549
Thr His Pro Glu Ser Thr *		
180		

<210> 93

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Met IL29 mutant T11P, C16X, Asn170

<221> VARIANT

<222> (16)...(16)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 93

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa			
1	5	10	15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe			
20	25	30	
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp			
35	40	45	
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu			
50	55	60	
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu			
85	90	95	
Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser			
165	170	175	
Thr His Pro Glu Ser Thr			
180			

<210> 94

<211> 546

<212> DNA
<213> Artificial Sequence

<220>
<223> IL29 mutant T10P, Asp169, C171X

<221> CDS
<222> (1)...(546)

<221> variation
<222> 30, 512, 513
<223> n = A, T, G, or C

<400> 94

ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc tgc cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys His	
1 5 10 15	
att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20 25 30	
aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35 40 45	
tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Gln	
50 55 60	
gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	
aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	
gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr	
165 170 175	
cac cct gag tcc acc tga	546
His Pro Glu Ser Thr *	
180	

<210> 95
<211> 181
<212> PRT
<213> Artificial Sequence

<220>
<223> IL29 mutant T10P, Asp169, C171X

<221> VARIANT
<222> (171)...(171)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 95
Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys His
1 5 10 15
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
20 25 30
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
35 40 45
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
50 55 60
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
65 70 75 80
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
85 90 95
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
100 105 110
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
115 120 125
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
130 135 140
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
145 150 155 160
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr
165 170 175
His Pro Glu Ser Thr
180

<210> 96
<211> 549
<212> DNA
<213> Artificial Sequence

<220>
<223> Met IL29 mutant T11P, Asp170, C172X

<221> CDS
<222> (1)...(549)

<221> variation
<222> 33, 515, 516
<223> n = A, T, G, or C

<400> 96
atg ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc tgc 48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys
1 5 10 15

cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc	96		
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe			
20	25	30	
aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144		
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp			
35	40	45	
agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192		
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu			
50	55	60	
cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240		
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80
ctg aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta	288		
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu			
85	90	95	
gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc	336		
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc	384		
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct	432		
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg	480		
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
cga gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca	528		
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser			
165	170	175	
acc cac cct gag tcc acc tga	549		
Thr His Pro Glu Ser Thr *			
180			

<210> 97
<211> 182
<212> PRT
<213> Artificial Sequence

<220>
<223> Met IL29 mutant T11P, Asp170, C172X

<221> VARIANT
<222> (172)...(172)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 97
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Cys
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe

20	25	30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp		
35	40	45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu		
50	55	60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr		
65	70	75
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu		
85	90	95
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala		
100	105	110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu		
115	120	125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser		
165	170	175
Thr His Pro Glu Ser Thr		
180		

<210> 98

<211> 546

<212> DNA

<213> Artificial Sequence

<220>

<223> IL29 mutant T10P, C15X, Asp169

<221> CDS

<222> (1)...(546)

<221> variation

<222> 30, 44, 45

<223> n = A, T, G, or C

<400> 98

ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc dnn cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa His	
1	5
10	15

att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20	25
30	

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35	40
45	

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50	55
60	

gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65	70
75	80

aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	

85	90	95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys 100	105	110	336
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His 115	120	125	384
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly 130	135	140	432
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg cga Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg 145	150	155	480
gac ctc aaa tat gtg gcc gat ggg gay ctg tgt ctg aga acg tca acc Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr 165	170	175	528
cac cct gag tcc acc tga His Pro Glu Ser Thr *			546
	180		

<210> 99
<211> 181
<212> PRT
<213> Artificial Sequence

<220>
<223> IL29 mutant T10P, C15X, Asp169

<221> VARIANT
<222> (15)...(15)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 99
Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa His
1 5 10 15
Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
20 25 30
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
35 40 45
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
50 55 60
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
65 70 75 80
Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
85 90 95
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
100 105 110
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
115 120 125
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
130 135 140
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
145 150 155 160
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr

His Pro Glu Ser Thr 165 180	170	175
 <210> 100 <211> 549 <212> DNA <213> Artificial Sequence		
<220> <223> Met IL29 mutant T11P, C16X, Asp170		
<221> CDS <222> (1)...(549)		
<221> variation <222> 33, 47, 48 <223> n = A, T, G, or C		
<400> 100		
atg ggc cct gtc ccc act tcc aag ccc acc ccn act ggg aag ggc dnn Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa 1 5 10 15		48
 cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe 20 25 30		
 aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp 35 40 45		
 agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu 50 55 60		
 cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr 65 70 75 80		
 ctg aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu 85 90 95		
 gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala 100 105 110		
 tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu 115 120 125		
 cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala 130 135 140		
 ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr 145 150 155 160		

cga gac ctc aaa tat gtg gcc gat ggg gay ctg tgt ctg aga acg tca	528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser	
165	170
	175

acc cac cct gag tcc acc tga	549
Thr His Pro Glu Ser Thr *	
180	

<210> 101
<211> 182
<212> PRT
<213> Artificial Sequence

<220>
<223> Met IL29 mutant T11P, C16X, Asp170

<221> VARIANT
<222> (16)...(16)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 101
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Pro Thr Gly Lys Gly Xaa
1 5 10 15
His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
100 105 110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
115 120 125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
130 135 140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
145 150 155 160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser
165 170 175
Thr His Pro Glu Ser Thr
180

<210> 102
<211> 546
<212> DNA
<213> Artificial Sequence

<220>
<223> IL29 mutant G18D, Asn169, C171X

<221> CDS
<222> (1)...(546)

<221> variation
<222> (512)...(513)

<223> n = A, T, G, or C

<400> 102

ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His	
1 5 10 15	

att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20 25 30	

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35 40 45	

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50 55 60	

gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	

aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	

cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	

atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	

cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	

tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	

gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr	
165 170 175	

cac cct gag tcc acc tga	546
His Pro Glu Ser Thr *	
180	

<210> 103

<211> 181

<212> PRT

<213> Artificial Sequence

<220>

<223> IL29 mutant G18D, Asn169, C171X

<221> VARIANT

<222> (171)...(171)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

```

<400> 103
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys His
  1           5           10           15
Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
  20          25          30
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
  35          40          45
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
  50          55          60
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
  65          70          75          80
Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
  85          90          95
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
  100         105         110
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
  115         120         125
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
  130         135         140
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
  145         150         155         160
Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr
  165         170         175
His Pro Glu Ser Thr
  180

```

<210> 104

<211> 549

<212> DNA

<213> Artificial Sequence

<220>

<223> Met IL29 mutant G19D, Asn170, C172X

<221> CDS

<222> (1)...(549)

<221> variation

<222> (515) . . . (516)

<223> n = A, T, G, or C

<400> 104

```

atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc 48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys
   1           5                  10                  15

```

```

cac att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20          25          30

```

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

```

agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc 192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
      50          55          60

```

cag	gtg	agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	gcc	ctg	acg	240
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	
65								70				75			80	
ctg	aag	gtc	ctg	gag	gcc	gct	ggc	cca	gcc	ctg	gag	gac	gtc	cta	288	
Leu	Lys	Val	Leu	Glu	Ala	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu	
85								90				95				
gac	cag	ccc	ctt	cac	acc	ctg	cac	atc	ctc	tcc	cag	ctc	cag	gcc	336	
Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala	
100								105				110				
tgt	atc	cag	cct	cag	ccc	aca	gca	ggg	ccc	agg	ccc	cgg	ggc	cgc	384	
Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu	
115								120				125				
cac	cac	tgg	ctg	cac	cgg	ctc	cag	gag	gcc	ccc	aaa	aag	gag	tcc	432	
His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	
130								135				140				
ggc	tgc	ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	tcc	cgc	ctc	ctc	acg	480
Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	
145								150				155			160	
cga	gac	ctc	aaa	tat	gtg	gcc	gat	ggg	aac	ctg	dnn	ctg	aga	acg	tca	528
Arg	Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Xaa	Leu	Arg	Thr	Ser	
165								170				175				
acc	cac	cct	gag	tcc	acc	tga									549	
Thr	His	Pro	Glu	Ser	Thr	*										
180																

<210> 105

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Met IL29 mutant G19D, Asn170, C172X

<221> VARIANT

<222> (172)...(172)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 105

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
1 5 10 15His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
20 25 30Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
35 40 45Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
50 55 60Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
85 90 95Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
100 105 110

Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser
 165 170 175
 Thr His Pro Glu Ser Thr
 180

<210> 106
 <211> 546
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL29 mutant C15X, G18D, Asn169

<221> CDS
 <222> (1)...(546)

<221> variation
 <222> (44)...(45)
 <223> n = A, T, G, or C

<400> 106
 ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn cac 48
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
 1 5 10 15

att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag 96
 Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt 144
 Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45

tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag 192
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60

gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg 240
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80

aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac 288
 Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95

cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt 336
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110

atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac 384
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125

cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc 432

His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	Gly	
130						135					140					
tgc	ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	ctc	acg	cga	480
Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	Arg	
145						150				155				160		
gac	ctc	aaa	tat	gtg	gcc	gat	ggg	aay	ctg	tgt	ctg	aga	acg	tca	acc	528
Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Cys	Leu	Arg	Thr	Ser	Thr	
						165			170			175				
cac	cct	gag	tcc	acc	tga											546
His	Pro	Glu	Ser	Thr	*											
					180											

<210> 107
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant C15X, G18D, Asn169

<221> VARIANT
 <222> (15)...(15)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 107
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
 1 5 10 15
 Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 108
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Met IL29 mutant C16X, G19D, Asn170

<221> CDS

<222> (1)...(549)

<221> variation

<222> (47)...(48)

<223> n = A, T, G, or C

<400> 108

atg	ggc	cct	gtc	ccc	act	tcc	aag	ccc	acc	aca	act	ggg	aag	ggc	dnn	48
Met	Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly	Lys	Gly	Xaa		
1	5							10				15				

cac	att	gay	agg	ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	gcg	agc	ttc	96
His	Ile	Asp	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	
					20			25				30				

aag	aag	gcc	agg	gac	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	aaa	aac	tgg	144
Lys	Lys	Ala	Arg	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	
					35			40			45					

agt	tgc	agc	tct	cct	gtc	ttc	ccc	ggg	aat	tgg	gac	ctg	agg	ctt	ctc	192
Ser	Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu	
					50			55			60					

cag	gtg	agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	gcc	ctg	acg	240
Gln	Val	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr			
					65			70			75		80			

ctg	aag	gtc	ctg	gag	gcc	gct	ggt	cca	gcc	ctg	gag	gac	gtc	cta	288
Leu	Lys	Val	Leu	Glu	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu	
					85			90			95				

gac	cag	ccc	ctt	cac	acc	ctg	cac	cac	atc	ctc	tcc	cag	ctc	cag	gcc	336
Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala	
								100			105		110			

tgt	atc	cag	cct	cag	ccc	aca	gca	ggg	ccc	agg	ccc	cgg	ggc	cgc	ctc	384
Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu	
						115		120			125					

cac	cac	tgg	ctg	cac	cgg	ctc	cag	gag	gcc	ccc	aaa	aag	gag	tcc	gct	432
His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	
						130		135			140					

ggc	tgc	ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	ctc	acg	480
Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	
						145		150			155		160			

cga	gac	ctc	aaa	tat	gtg	gcc	gat	ggg	aay	ctg	tgt	ctg	aga	acg	tca	528
Arg	Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Cys	Leu	Arg	Thr	Ser	
						165		170			175					

acc	cac	cct	gag	tcc	acc	tga									549
Thr	His	Pro	Glu	Ser	Thr	*									
					180										

<210> 109

<211> 182

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant C16X, G19D, Asn170

<221> VARIANT
 <222> (16)...(16)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 109
 Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
 1 5 10 15
 His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95
 Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
 100 105 110
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser
 165 170 175
 Thr His Pro Glu Ser Thr
 180

<210> 110
 <211> 546
 <212> DNA
 <213> qArtificial Sequence

<220>
 <223> IL29 mutant G18D, Asp169, C171X

<221> CDS
 <222> (1)...(546)

<221> variation
 <222> (512)...(513)
 <223> n = A, T, G, or C

<400> 110
 ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac 48
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His
 1 5 10 15
 att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag 96
 Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30

aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144		
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser			
35	40	45	
tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192		
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln			
50	55	60	
gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240		
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu			
65	70	75	80
aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta gac	288		
Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp			
85	90	95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336		
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys			
100	105	110	
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384		
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His			
115	120	125	
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432		
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly			
130	135	140	
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480		
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg			
145	150	155	160
gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca acc	528		
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr			
165	170	175	
cac cct gag tcc acc tga	546		
His Pro Glu Ser Thr *			
180			

<210> 111
<211> 181
<212> PRT
<213> Artificial Sequence

<220>
<223> IL29 mutant G18D, Asp169, C171X

<221> VARIANT
<222> (171)...(171)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 111
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His
1 5 10 15
Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
20 25 30
Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
35 40 45
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln

50	55	60
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu		
65	70	75
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp		80
85	90	95
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys		
100	105	110
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His		
115	120	125
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly		
130	135	140
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg		
145	150	155
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser Thr		160
165	170	175
His Pro Glu Ser Thr		
180		

<210> 112

<211> 549

<212> DNA

<213> Artificial Sequence

<220>

<223> Met IL29 mutant G19D, Asp170, C172X

<221> CDS

<222> (1)...(549)

<221> variation

<222> (515)...(516)

<223> n = A, T, G, or C

<400> 112

atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc	48
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys	
1	5
10	15

cac att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc	96
His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe	
20	25
30	

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg	144
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp	
35	40
45	

agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc	192
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu	
50	55
60	

cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg	240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr	
65	70
75	80

ctg aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta	288
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu	
85	90
95	

gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc	336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala	

100	105	110	
tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc			384
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct			432
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg			480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
cga gac ctc aaa tat gtg gcc gat ggg gay ctg dnn ctg aga acg tca			528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser			
165	170	175	
acc cac cct gag tcc acc tga			549
Thr His Pro Glu Ser Thr *			
180			

<210> 113

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Met IL29 mutant G19D, Asp170, C172X

<221> VARIANT

<222> (172)...(172)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 113

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys			
1	5	10	15
His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe			
20	25	30	
Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp			
35	40	45	
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu			
50	55	60	
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80
Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu			
85	90	95	
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Xaa Leu Arg Thr Ser			
165	170	175	
Thr His Pro Glu Ser Thr			
180			

<210> 114
 <211> 546
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> IL29 mutant C15X, G18D, Asp169

 <221> CDS
 <222> (1)...(546)

 <221> variation
 <222> (44)...(45)
 <223> n = A, T, G, or C

 <400> 114

ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn cac	48
Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His	
1 5 10 15	
att gay agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag	96
Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys	
20 25 30	
aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt	144
Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser	
35 40 45	
tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag	192
Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln	
50 55 60	
gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg	240
Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu	
65 70 75 80	
aag gtc ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac	288
Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp	
85 90 95	
cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt	336
Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys	
100 105 110	
atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac	384
Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His	
115 120 125	
cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc	432
His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly	
130 135 140	
tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga	480
Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg	
145 150 155 160	
gac ctc aaa tat gtg gcc gat ggg gay ctg tgt ctg aga acg tca acc	528
Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr	
165 170 175	

cac cct gag tcc acc tga
 His Pro Glu Ser Thr *
 180

546

<210> 115
 <211> 181
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL29 mutant C15X, G18D, Asp169

<221> VARIANT
 <222> (15)...(15)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 115
 Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa His
 1 5 10 15
 Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys
 20 25 30
 Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser
 35 40 45
 Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln
 50 55 60
 Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 65 70 75 80
 Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp
 85 90 95
 Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys
 100 105 110
 Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His
 115 120 125
 His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly
 130 135 140
 Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg
 145 150 155 160
 Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser Thr
 165 170 175
 His Pro Glu Ser Thr
 180

<210> 116
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant C16X, G19D, Asp170

<221> CDS
 <222> (1)...(549)

<221> variation
 <222> (47)...(48)
 <223> n = A, T, G, or C

<400> 116

atg ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc dnn 48

Met	Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly	Lys	Gly	Xaa	
1				5				10				15			
														96	
cac	att	gay	agg	ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	gcg	agc	ttc
His	Ile	Asp	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe
20							25					30			
														144	
aag	aag	gcc	agg	gac	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	aaa	aac	tgg
Lys	Lys	Ala	Arg	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp
35							40					45			
														192	
agt	tgc	agc	tct	cct	gtc	ttc	ccc	ggg	aat	tgg	gac	ctg	agg	ctt	ctc
Ser	Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu
50						55					60				
														240	
cag	gtg	agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	gcc	ctg	acg
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr
65						70				75				80	
														288	
ctg	aag	gtc	ctg	gag	gcc	gct	gct	ggc	cca	gcc	ctg	gag	gac	gtc	cta
Leu	Lys	Val	Leu	Glu	Ala	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu
85						90				95					
														336	
gac	cag	ccc	ctt	cac	acc	ctg	cac	atc	ctc	tcc	cag	ctc	cag	gcc	
Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala
100						105				110					
														384	
tgt	atc	cag	cct	cag	ccc	aca	gca	ggg	ccc	agg	ccc	cgg	ggc	cgc	ctc
Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu
115						120				125					
														432	
cac	cac	tgg	ctg	cac	cg	ctc	cag	gag	gcc	ccc	aaa	aag	gag	tcc	gct
His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala
130						135				140					
														480	
ggc	tgc	ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	ctc	acg
Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr
145						150				155			160		
														528	
cga	gac	ctc	aaa	tat	gtg	gcc	gat	ggg	gay	ctg	tgt	ctg	aga	acg	tca
Arg	Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asp	Leu	Cys	Leu	Arg	Thr	Ser
165						170				175					
														549	
acc	cac	cct	gag	tcc	acc	tga									
Thr	His	Pro	Glu	Ser	Thr	*									
180															

<210> 117
 <211> 182
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Met IL29 mutant C16X, G19D, Asp170

<221> VARIANT
 <222> (16)...(16)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 117

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Xaa
 1 5 10 15
 His Ile Asp Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95
 Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
 100 105 110
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asp Leu Cys Leu Arg Thr Ser
 165 170 175
 Thr His Pro Glu Ser Thr
 180

<210> 118

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Signal sequence

<221> CDS

<222> (1)...(57)

<400> 118

atg gct gca gct tgg acc gtg gtg ctg gtg act ttg gtg cta ggc ttg 48
 Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val Leu Gly Leu
 1 5 10 15

gcc gtg gca
 Ala Val Ala

57

<210> 119

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Signal sequence

<400> 119

Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val Leu Gly Leu
 1 5 10 15
 Ala Val Ala

<210> 120
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Signal sequence

<221> CDS
 <222> (1)...(66)

<400> 120

atg	gtg	ccc	acc	aca	ttg	gct	tgg	acc	gtg	gtg	ctg	gtg	act	ttg	gtg	48
Met	Val	Pro	Thr	Thr	Leu	Ala	Trp	Thr	Val	Val	Leu	Val	Thr	Leu	Val	
1	5				10						15					

cta ggc ttg gcc gtg gca

Leu	Gly	Leu	Ala	Val	Ala	66
		20				

<210> 121
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Signal sequence

<400> 121

Met	Val	Pro	Thr	Thr	Leu	Ala	Trp	Thr	Val	Val	Leu	Val	Thr	Leu	Val	48
1	5				10						15					
Leu	Gly	Leu	Ala	Val	Ala											
			20													

<210> 122
 <211> 528
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-28B C48S

<221> CDS
 <222> (1)...(528)

<221> variation
 <222> (143)...(144)
 <223> n = A, T, G, or C

<400> 122

gtt	cct	gtc	gcc	agg	ctc	cgc	ggg	gct	ctc	ccg	gat	gca	agg	ggc	tgc	48
Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys	
1	5				10						15					

cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc ttt

His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe	96
			20				25				30					

aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac dnn Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp Xaa 35 40 45	144
aag tgc cgc tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag ctg Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu 50 55 60	192
cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg acg Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr 65 70 75 80	240
ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg ggg gat Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly Asp 85 90 95	288
gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag ctc Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu 100 105 110	336
cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg ggc Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly 115 120 125	384
cgc ctc cac cat tgg ctg cac cgg ctc cag gag gcc cca aaa aag gag Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu 130 135 140	432
tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc ctc Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu 145 150 155 160	480
ctc acg cga gac ctg aat tgt gtt gcc agc ggg gac ctg tgt gtc tga Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val *	528
165 170 175	

<210> 123
<211> 175
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (48)...(48)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> IL-28B C48S

<400> 123
Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly Cys
1 5 10 15
His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
20 25 30
Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp Xaa
35 40 45
Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80

Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly Asp
 85 90 95
 Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu
 100 105 110
 Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly
 115 120 125
 Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu
 130 135 140
 Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu
 145 150 155 160
 Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 124

<211> 531

<212> DNA

<213> Artificial Sequence

<220>

<223> Met IL-28B C49S

<221> CDS

<222> (1)...(531)

<221> variation

<222> (146)...(147)

<223> n = A, T, G, or C

<400> 124

atg gtt cct gtc gcc agg ctc cgc ggg gct ctc ccg gat gca agg ggc 48
 Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15

tgc cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc 96
 Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
 20 25 30

ttt aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac 144
 Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Ile Lys Asp
 35 40 45

dnn aag tgc cgc tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag 192
 Xaa Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60

ctg cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg 240
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80

acg ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg ggg 288
 Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly
 85 90 95

gat gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag 336
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110

ctc cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg 384
 Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125

ggc cgc ctc cac cat tgg ctg cac cgg ctc cag gag gcc cca aaa aag	432
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
gag tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc	480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
ctc ctc acg cga gac ctg aat tgt gtt gcc agc ggg gac ctg tgt gtc	528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	
tga	531
*	

<210> 125
 <211> 176
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> (49)...(49)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> Met IL-28B C49S

<400> 125	
Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly	
1 5 10 15	
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala	
20 25 30	
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp	
35 40 45	
Xaa Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln	
50 55 60	
Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu	
65 70 75 80	
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly	
85 90 95	
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	
100 105 110	
Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg	
115 120 125	
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	

<210> 126
 <211> 528
 <212> DNA
 <213> Artificial Sequence

<220>

<223> IL-28B C50S

<221> CDS

<222> (1) ... (528)

<221> variation

<222> (149) ... (150)

<223> n = A, T, G, or C

<400> 126

gtt	cct	gtc	gcc	agg	ctc	cgc	ggg	gct	ctc	ccg	gat	gca	agg	ggc	tgc	48
Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys	
1	5							10				15				

cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	ttt	96
His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe	
								25				30				

aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	ctg	aag	gac	tgc	144
Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	Cys	
								35				40		45		

aag	dnn	cgc	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	ctg	192
Lys	Xaa	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	Leu	
								50				55		60		

cag	gtg	agg	gag	cgc	ccc	gtg	gct	ttg	gag	gct	gag	ctg	gcc	ctg	acg	240
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	
								65				70		75		

ctg	aag	gtt	ctg	gag	gcc	acc	gct	gac	act	gac	cca	gcc	ctg	ggg	gat	288
Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly	Asp	
								85				90		95		

gtc	ttg	gac	cag	ccc	ctt	cac	acc	ctg	cac	cat	atc	ctc	tcc	cag	ctc	336
Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	
								100				105		110		

cgg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cgg	ggc	384
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly	
								115				120		125		

cgc	ctc	cac	cat	tgg	ctg	cac	cg	cag	gcc	cca	aaa	aag	gag		432
Arg	Leu	His	His	Trp	Leu	His	Arg	Leu	Gln	Ala	Pro	Lys	Lys	Glu	
								130				135		140	

tcc	cct	ggc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	480
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu
								145				150		155	

ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agc	ggg	gac	ctg	tgt	gtc	tga	528
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	*	
								165				170		175		

<210> 127

<211> 175

<212> PRT

<213> Artificial Sequence

<220>

<221> VARIANT

<222> (50)...(50)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> IL-28B C50S

<400> 127

Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys
1				5				10					15		
His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe
				20				25				30			
Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	Cys	
				35				40			45				
Lys	Xaa	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	Leu
				50				55			60				
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr
				65				70			75		80		
Leu	Lys	Val	Leu	Glu	Ala	Thr	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly	Asp
				85				90			95				
Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu
				100				105			110				
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly
				115				120			125				
Arg	Leu	His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu
				130				135			140				
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu
				145				150			155		160		
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
				165				170			175				

<210> 128

<211> 531

<212> DNA

<213> Artificial Sequence

<220>

<223> Met IL-28B C51S

<221> CDS

<222> (1)...(531)

<221> variation

<222> (152)...(153)

<223> n = A, T, G, or C

<400> 128

atg	gtt	cct	gtc	gcc	agg	ctc	cgc	ggg	gct	ctc	ccg	gat	gca	agg	ggc	48
Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	
1					5				10				15			

tgc	cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	96
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	
					20				25			30				

ttt	aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	aag	gac	144
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Ser	Leu	Leu	Lys	Asp		
					35			40			45				

tgc	aag	dnn	cgc	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	192
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln			
50	55	60	
ctg cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg			240
Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu			
65	70	75	80
acg ctg aag gtt ctg gag gcc acc gct gac act gac cca gcc ctg ggg			288
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly			
85	90	95	
gat gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag			336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln			
100	105	110	
ctc cgg gcc tgt atc cag cct cag ccc acg gca ggg ccc agg acc cgg			384
Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg			
115	120	125	
ggc cgc ctc cac cat tgg ctg cac cgg ctc cag gag gcc cca aaa aag			432
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys			
130	135	140	
gag tcc cct ggc tgc ctc gag gcc tct gtc acc ttc aac ctc ttc cgc			480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg			
145	150	155	160
ctc ctc acg cga gac ctg aat tgt gtt gcc agc ggg gac ctg tgt gtc			528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val			
165	170	175	
tga			531
*			

<210> 129
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (51)...(51)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> Met IL-28B C51S

<400> 129
Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly
1 5 10 15
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
20 25 30
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
35 40 45
Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
50 55 60
Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
65 70 75 80
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Gly
85 90 95

Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		
100	105	110
Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		
115	120	125
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys		
130	135	140
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		
145	150	155
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		
165	170	175

<210> 130

<211> 528

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-28B C48S T87S H135Y

<221> CDS

<222> (1)...(528)

<221> variation

<222> 143, 144, 261

<223> n = A, T, G, or C

<400> 130

gtt cct gtc gcc agg ctc cgc ggg gct ctc ccg gat gca agg ggc tgc		48
Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly Cys		
1	5	10
		15

cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc ttt		96
His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe		
20	25	30

aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac dnn		144
Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp Xaa		
35	40	45

aag tgc cgc tcc cgc ctc ttc ccc agg acc tgg gac ctg ctg agg ctg		192
Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu		
50	55	60

cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg acg		240
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr		
65	70	75
		80

ctg aag gtt ctg gag gcc wsn gct gac act gac cca gcc ctg ggg gat		288
Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly Asp		
85	90	95

gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag ctc		336
Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu		
100	105	110

cgg gcc tgt atc cag ccc acg gca ggg ccc agg acc cgg ggc		384
Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly		
115	120	125

cgc ctc cac cat tgg ctg tay cgg ctc cag gag gcc cca aaa aag gag		432
---	--	-----

Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	
130								135							140	
tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	480
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	
145												155			160	
ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agc	ggg	gac	ctg	tgt	gtc	tga	528
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	*	
												165		170	175	

<210> 131
<211> 175
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (48)...(48)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<221> VARIANT
<222> (87)...(87)
<223> Xaa = Ser

<223> IL-28B C48S T87S H135Y

<400> 131
Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly Cys
1 5 10 15
His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
20 25 30
Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp Xaa
35 40 45
Lys Cys Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu
50 55 60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
65 70 75 80
Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly Asp
85 90 95
Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu
100 105 110
Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly
115 120 125
Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys Glu
130 135 140
Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu
145 150 155 160
Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
165 170 175

<210> 132
<211> 531
<212> DNA
<213> Artificial Sequence

<220>
<223> Met IL-28B C49S T88S H136Y

<221> CDS

<222> (1)...(531)

<221> variation

<222> 146, 147, 264

<223> n = A, T, G, or C

<400> 132

atg	gtt	cct	gtc	gcc	agg	ctc	cgc	ggg	gct	ctc	ccg	gat	gca	agg	ggc	48
Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	
1	5					10				15						

tgc	cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	96
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	
20						25				30						

ttt	aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	ctg	aag	gac	144
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	
35					40					45						

dnn	aag	tgc	cgc	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	192
Xaa	Lys	Cys	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	
50					55					60						

ctg	cag	gtg	agg	gag	cgc	ccc	gtg	gct	ttg	gag	gct	gag	ctg	gcc	ctg	240
Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	
65					70				75				80			

acg	ctg	aag	gtt	ctg	gag	gcc	wsn	gct	gac	act	gac	cca	gcc	ctg	ggg	288
Thr	Leu	Lys	Val	Ieu	Glu	Ala	Xaa	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly	
85					90					95						

gat	gtc	ttg	gac	cag	ccc	ctt	cac	acc	ctg	cac	cat	atc	ctc	tcc	cag	336
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	
100					105				110							

ctc	cgg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cgg	384
Leu	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	
115					120				125							

ggc	cgc	ctc	cac	cat	tgg	ctg	tay	cgg	ctc	cag	gag	gcc	cca	aaa	aag	432
Gly	Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	
130					135				140							

gag	tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	480
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145					150				155			160				

ctc	ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agc	ggg	gac	ctg	tgt	gtc	528
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
165					170				175							

tga	*															531
-----	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	-----

<210> 133

<211> 176

<212> PRT

<213> Artificial Sequence

<220>

<221> VARIANT

<222> (49)...(49)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<221> VARIANT

<222> (88)...(88)

<223> Xaa = Ser

<223> Met IL-28B C49S T88S H136Y

<400> 133

Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly
1				5			10				15				
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala
				20			25				30				
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	
				35			40				45				
Xaa	Lys	Cys	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln
				50			55				60				
Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu
				65			70			75		80			
Thr	Leu	Lys	Val	Leu	Glu	Ala	Xaa	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly
				85			90				95				
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln
				100			105				110				
Leu	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg
				115			120				125				
Gly	Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys
				130			135				140				
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg
				145			150			155		160			
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val
				165			170				175				

<210> 134

<211> 528

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-28B C50S T87S H135Y

<221> CDS

<222> (1)...(528)

<221> variation

<222> 149, 150, 261

<223> n = A, T, G, or C

<400> 134

gtt	cct	gtc	gcc	agg	ctc	cgc	ggg	gct	ctc	ccg	gat	gca	agg	ggc	tgc
1				5				10			15				48
Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly	Cys

cac	ata	gcc	cag	ttc	aag	tcc	ctg	tct	cca	cag	gag	ctg	cag	gcc	ttt
															96
His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala	Phe
				20			25			30					

aag	agg	gcc	aaa	gat	gcc	tta	gaa	gag	tcg	ctt	ctg	ctg	aag	gac	tgc	144
Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Leu	Lys	Asp	Cys	
35					40						45					
aag	dnn	cgc	tcc	cgc	ctc	ttc	ccc	agg	acc	tgg	gac	ctg	agg	cag	ctg	192
Lys	Xaa	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln	Leu	
50					55					60						
cag	gtg	agg	gag	cgc	ccc	gtg	gct	ttg	gag	gct	gag	ctg	gcc	ctg	acg	240
Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	
65					70					75			80			
ctg	aag	gtt	ctg	gag	gcc	wsn	gct	gac	act	gac	cca	gcc	ctg	ggg	gat	288
Leu	Lys	Val	Leu	Glu	Ala	Xaa	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly	Asp	
85					90					95						
gtc	ttg	gac	cag	ccc	ctt	cac	acc	ctg	cac	cat	atc	ctc	tcc	cag	ctc	336
Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	
100					105					110						
cgg	gcc	tgt	atc	cag	cct	cag	ccc	acg	gca	ggg	ccc	agg	acc	cgg	ggc	384
Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	Gly	
115					120					125						
cgc	ctc	cac	cat	tgg	ctg	tay	cgg	ctc	cag	gag	gcc	cca	aaa	aag	gag	432
Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	
130					135					140						
tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	480
Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	
145					150					155			160			
ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agc	ggg	gac	ctg	tgt	gtc	tga	528
Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	*	
165					170					175						

<210> 135
 <211> 175
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> (50)...(50)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<221> VARIANT
 <222> (87)...(87)
 <223> Xaa = Ser
 <223> IL-28B C50S T87S H135Y

<400> 135
 Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly Cys
 1 5 10 15
 His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe
 20 25 30
 Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp Cys

35	40	45
Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln Leu		
50	55	60
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr		
65	70	75
Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly Asp		
85	90	95
Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu		
100	105	110
Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg Gly		
115	120	125
Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys Glu		
130	135	140
Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu		
145	150	155
Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		
165	170	175

<210> 136

<211> 531

<212> DNA

<213> Artificial Sequence

<220>

<223> Met IL-28B C51S T88S H136Y

<221> CDS

<222> (1)...(531)

<221> variation

<222> 152, 153, 264

<223> n = A, T, G, or C

<400> 136

atg gtt cct gtc gcc agg ctc cgc ggg gct ctc ccg gat gca agg ggc	48		
Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly			
1	5	10	15

tgc cac ata gcc cag ttc aag tcc ctg tct cca cag gag ctg cag gcc	96	
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala		
20	25	30

ttt aag agg gcc aaa gat gcc tta gaa gag tcg ctt ctg ctg aag gac	144	
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp		
35	40	45

tgc aag dnn cgc tcc cgc ctc ttc ccc agg acc tgg gac ctg agg cag	192	
Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln		
50	55	60

ctg cag gtg agg gag cgc ccc gtg gct ttg gag gct gag ctg gcc ctg	240		
Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu			
65	70	75	80

acg ctg aag gtt ctg gag gcc wsn gct gac act gac cca gcc ctg ggg	288	
Thr Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly		
85	90	95

gat gtc ttg gac cag ccc ctt cac acc ctg cac cat atc ctc tcc cag	336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	

100	105	110														
ctc	cg	g	384													
Leu	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg	
115				120					125							
ggc	cgc	ctc	cac	cat	tgg	ctg	tay	cg	ctc	cag	gag	gcc	cca	aaa	aag	384
Gly	Arg	Leu	His	His	Trp	Leu	Tyr	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	432
130				135				140								
gag	tcc	cct	ggc	tgc	ctc	gag	gcc	tct	gtc	acc	tcc	aac	ctc	ttc	cgc	480
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145				150				155			160					
ctc	ctc	acg	cga	gac	ctg	aat	tgt	gtt	gcc	agc	ggg	gac	ctg	tgt	gtc	528
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val	
165				170				175								
tga															531	
*																

<210> 137
 <211> 176
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> (51)...(51)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<221> VARIANT
 <222> (88)...(88)
 <223> Xaa = Ser

<223> Met IL-28B C51S T88S H136Y

<400> 137
 Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15
 Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
 20 25 30
 Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
 35 40 45
 Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
 145 150 155 160
 Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val

165

170

175

<210> 138

<211> 543

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 C170X, truncated after N-terminal Methionine
and Glycine

<221> variation

<222> (509)...(510)

<223> n = A, T, G, or C

<221> CDS

<222> (1)...(543)

<400> 138

cct	gtc	ccc	act	tcc	aag	ccc	acc	aca	act	ggg	aag	ggc	tgc	cac	att	48
Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Thr	Gly	Lys	Gly	Cys	His	Ile	
1		5				10								15		

ggc	agg	ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	gcg	agc	ttc	aag	aag	96
Gly	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	Lys	Lys	
20				25								30				

gcc	agg	gac	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	aaa	aac	tgg	agt	tgc	144
Ala	Arg	Asp	Ala	Leu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	Ser	Cys		
35			40								45					

agc	tct	cct	gtc	ttc	ccc	ggg	aat	tgg	gac	ctg	agg	ctt	ctc	cag	gtg	192
Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Gln	Val		
50			55							60						

agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	gcc	ctg	acg	ctg	aag	240
Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	Leu	Lys	
65			70						75				80			

gtc	ctg	gag	gcc	gct	ggc	cca	gcc	ctg	gag	gac	gtc	cta	gac	cag	288
Val	Leu	Glu	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu	Asp	Gln	
85			90							95					

ccc	ctt	cac	acc	ctg	cac	cac	atc	ctc	tcc	cag	ctc	cag	gcc	tgt	atc	336
Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala	Cys	Ile	
100				105						110						

cag	cct	cag	ccc	aca	gca	ggg	ccc	agg	ccc	cgg	ggc	cgc	ctc	cac	cac	384
Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu	His	His	
115			120								125					

tgg	ctg	cac	cgg	ctc	cag	gag	gcc	ccc	aaa	aag	gag	tcc	gct	ggc	tgc	432
Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	Gly	Cys	
130			135							140						

ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	ctc	acg	cga	gac	480
Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	Arg	Asp
145			150						155				160		

ctc	aaa	tat	gtg	gcc	gat	ggg	aac	ctg	dnn	ctg	aga	acg	tca	acc	cac	528
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His
165 170 175

cct gag tcc acc tga 543
Pro Glu Ser Thr *
180

<210> 139
<211> 180
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (170)...(170)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> IL-29 C170X, truncated after N-terminal Methionine
and Glycine

<400> 139
Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile
1 5 10 15
Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys
20 25 30
Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys
35 40 45
Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val
50 55 60
Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys
65 70 75 80
Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln
85 90 95
Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile
100 105 110
Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His
115 120 125
Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys
130 135 140
Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp
145 150 155 160
Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His
165 170 175
Pro Glu Ser Thr
180

<210> 140
<211> 540
<212> DNA
<213> Artificial Sequence

<220>
<223> IL-29 C169X, truncated after N-terminal
Methionine, Glycine, and Proline

<221> variation
<222> (506)...(507)
<223> n = A, T, G, or C

<221> CDS
<222> (1)...(540)

<400> 140
gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac att ggc 48
Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly
1 5 10 15

agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc 96
Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala
20 25 30

agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc 144
Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser
35 40 45

tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg 192
Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg
50 55 60

gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc 240
Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val
65 70 75 80

ctg gag gcc gct ggc cca gcc ctg gag gac gtc cta gac cag ccc 288
Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro
85 90 95

ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag 336
Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln
100 105 110

cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg 384
Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp
115 120 125

ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg 432
Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu
130 135 140

gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg cga gac ctc 480
Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu
145 150 155 160

aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca acc cac cct 528
Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro
165 170 175

gag tcc acc tga 540
Glu Ser Thr *

<210> 141
<211> 179
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (169)...(169)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<223> L-29 C169X, truncated after N-terminal Methionine, Glycine, and Proline

<400> 141

Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly	Lys	Gly	Cys	His	Ile	Gly
1					5			10				15		
Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	Lys	Lys
														Ala
					20			25				30		
Arg	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	Ser	Cys
												45		
Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu	Gln	Val
												60		Arg
Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	Leu	Lys
												80		Val
Leu	Glu	Ala	Ala	Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu	Asp	Gln
												95		Pro
Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala	Cys	Ile
						100						110		Gln
Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu	His	His
						115						125		Trp
Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	Gly	Cys
						130						140		Leu
Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	Arg	Asp
						145						155		Leu
Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Xaa	Leu	Arg	Thr	Ser	Thr	His
												175		Pro
Glu	Ser	Thr												

<210> 142

<211> 537

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 C168X, truncated after N-terminal Methionine, Glycine, Proline, and Valine

<221> variation

<222> (503)...(504)

<223> n = A, T, G, or C

<221> CDS

<222> (1)...(537)

<400> 142

ccc	act	tcc	aag	ccc	acc	aca	act	ggg	aag	ggc	tgc	cac	att	ggc	agg	48
Pro	Thr	Ser	Lys	Pro	Thr	Thr	Thr	Gly	Lys	Gly	Cys	His	Ile	Gly	Arg	
1				5				10				15				

ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	gcg	agc	ttc	aag	aag	gcc	agg	96
Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	Lys	Lys	Ala	Arg	
					20			25				30				

gac	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	aaa	aac	tgg	agt	tgc	agc	tct	144
Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	Ser	Cys	Ser	Ser	
					35			40				45				

cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag	192
Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu	
50 55 60	
cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg	240
Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu	
65 70 75 80	
gag gcc gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt	288
Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu	
85 90 95	
cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct	336
His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro	
100 105 110	
cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg	384
Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu	
115 120 125	
cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag	432
His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu	
130 135 140	
gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg cga gac ctc aaa	480
Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys	
145 150 155 160	
tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca acc cac cct gag	528
Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu	
165 170 175	
tcc acc tga	537
Ser Thr *	

<210> 143

<211> 178

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-29 C168X, truncated after N-terminal
Methionine, Glycine, Proline, and Valine

<221> VARIANT

<222> (168)...(168)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 143

Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg	
1 5 10 15	
Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg	
20 25 30	
Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser	
35 40 45	
Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu	
50 55 60	
Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu	
65 70 75 80	

Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu
 85 90 95
 His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro
 100 105 110
 Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu
 115 120 125
 His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu
 130 135 140
 Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys
 145 150 155 160
 Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu
 165 170 175
 Ser Thr

<210> 144
 <211> 534
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-29 C167X, truncated after N-terminal
 Methionine, Glycine, Proline, Valine, and Proline

<221> variation
 <222> (500)...(501)
 <223> n = A, T, G, or C

<221> CDS
 <222> (1)...(534)

<400> 144
 act tcc aag ccc acc aca act ggg aag ggc tgc cac att ggc agg ttc 48
 Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe
 1 5 10 15

aaa tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg gac 96
 Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp
 20 25 30

gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct cct 144
 Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro
 35 40 45

gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag cgc 192
 Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg
 50 55 60

cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg gag 240
 Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu
 65 70 75 80

gcc gct gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt cac 288
 Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His
 85 90 95

acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct cag 336
 Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln
 100 105 110

ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg cac	384
Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His	
115 120 125	
cg ^g ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag gca	432
Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala	
130 135 140	
tct gtc acc ttc aac ctc ttc cgc ctc acg cga gac ctc aaa tat	480
Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr	
145 150 155 160	
gtg gcc gat ggg aac ctg dnn ctg aga acg tca acc cac cct gag tcc	528
Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser	
165 170 175	
acc tga	534
Thr *	

<210> 145

<211> 177

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-29 C167X, truncated after N-terminal
Methionine, Glycine, Proline, Valine, and Proline

<221> VARIANT

<222> (167)...(167)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 145

Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe	
1 5 10 15	
Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp	
20 25 30	
Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro	
35 40 45	
Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg	
50 55 60	
Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu	
65 70 75 80	
Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His	
85 90 95	
Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln	
100 105 110	
Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His	
115 120 125	
Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala	
130 135 140	
Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr	
145 150 155 160	
Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser	
165 170 175	
Thr	

<210> 146
 <211> 531
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-29 C166X, truncated after N-terminal
 Methionine, Glycine, Proline, Valine, Proline, and
 Threonine

<221> variation
 <222> (497)...(498)
 <223> n = A, T, G, or C

<221> CDS
 <222> (1)...(531)

<400> 146

tcc aag ccc acc aca act ggg aag ggc tgc cac att ggc agg ttc aaa	48
Ser Lys Pro Thr Thr Gly Lys Gly His Ile Gly Arg Phe Lys	
1 5 10 15	
tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg gac gcc	96
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala	
20 25 30	
ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct cct gtc	144
Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val	
35 40 45	
ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag cgc cct	192
Phe Pro Gly Asn Trp Asp Leu Arg Leu Gln Val Arg Glu Arg Pro	
50 55 60	
gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg gag gcc	240
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala	
65 70 75 80	
gct gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt cac acc	288
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr	
85 90 95	
ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct cag ccc	336
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro	
100 105 110	
aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg cac cgg	384
Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg	
115 120 125	
ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag gca tct	432
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser	
130 135 140	
gtc acc ttc aac ctc ttc cgc ctc acg cga gac ctc aaa tat gtg	480
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val	
145 150 155 160	
gcc gat ggg aac ctg dnn ctg aga acg tca acc cac cct gag tcc acc	528
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr	
165 170 175	

tga
*

531

<210> 147
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-29 C166X, truncated after N-terminal
Methionine, Glycine, Proline, Valine, Proline, and
Threonine

<221> VARIANT
<222> (166)...(166)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 147
Ser Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys
1 5 10 15
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala
20 25 30
Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val
35 40 45
Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro
50 55 60
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala
65 70 75 80
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr
85 90 95
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro
100 105 110
Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg
115 120 125
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser
130 135 140
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val
145 150 155 160
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr
165 170 175

<210> 148
<211> 528
<212> DNA
<213> Artificial Sequence

<220>
<223> IL-29 C165X, truncated after N-terminal
Methionine, Glycine, Proline, Valine, Proline,
Threonine, and Serine

<221> variation
<222> (494)...(495)
<223> n = A, T, G, or C

<221> CDS
<222> (1)...(528)

<400> 148

aag ccc acc aca act ggg aag ggc tgc cac att ggc agg ttc aaa tct	48
Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys Ser	
1 5 10 15	
ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg gac gcc ttg	96
Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala Leu	
20 25 30	
gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct cct gtc ttc	144
Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val Phe	
35 40 45	
ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag cgc cct gtg	192
Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro Val	
50 55 60	
gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg gag gcc gct	240
Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala Ala	
65 70 75 80	
gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt cac acc ctg	288
Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr Leu	
85 90 95	
cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct cag ccc aca	336
His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro Thr	
100 105 110	
gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg cac cgg ctc	384
Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg Leu	
115 120 125	
cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag gca tct gtc	432
Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser Val	
130 135 140	
acc ttc aac ctc ttc cgc ctc acg cga gac ctc aaa tat gtg gcc	480
Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val Ala	
145 150 155 160	
gat ggg aac ctg dnn ctg aga acg tca acc cac cct gag tcc acc tga	528
Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr *	
165 170 175	

<210> 149

<211> 175

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-29 C165X, truncated after N-terminal
 Methionine, Glycine, Proline, Valine, Proline,
 Threonine, and Serine

<221> VARIANT

<222> (165)...(165)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 149

Lys	Pro	Thr	Thr	Thr	Gly	Lys	Gly	Cys	His	Ile	Gly	Arg	Phe	Lys	Ser
1															
														15	
Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	Phe	Lys	Lys	Ala	Arg	Asp	Ala	Leu
														30	
Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn	Trp	Ser	Cys	Ser	Ser	Pro	Val	Phe
														45	
Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu	Leu	Gln	Val	Arg	Glu	Arg	Pro	Val
														60	
Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	Thr	Leu	Lys	Val	Leu	Glu	Ala	Ala
														80	
Ala	Gly	Pro	Ala	Leu	Glu	Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu
														95	
His	His	Ile	Leu	Ser	Gln	Leu	Gln	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr
														110	
Ala	Gly	Pro	Arg	Pro	Arg	Gly	Arg	Leu	His	His	Trp	Leu	His	Arg	Leu
														125	
Gln	Glu	Ala	Pro	Lys	Lys	Glu	Ser	Ala	Gly	Cys	Leu	Glu	Ala	Ser	Val
														140	
Thr	Phe	Asn	Leu	Phe	Arg	Leu	Leu	Thr	Arg	Asp	Leu	Lys	Tyr	Val	Ala
														160	
Asp	Gly	Asn	Leu	Xaa	Leu	Arg	Thr	Ser	Thr	His	Pro	Glu	Ser	Thr	
														175	
165															

<210> 150

<211> 552

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 Leu insert after N-terminal Met, C173X

<221> variation

<222> (518)...(519)

<223> n = A, T, G, or C

<221> CDS

<222> (1)...(552)

<400> 150

atg	ytn	ggc	cct	gtc	ccc	act	tcc	aag	ccc	acc	aca	act	ggg	aag	ggc	48
Met	Leu	Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly	Lys	Gly		
1														15		

tgc	cac	att	ggc	agg	ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	gcg	agc	96
Cys	His	Ile	Gly	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Ala	Ser	
														20	30	

ttc	aag	aag	gcc	agg	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	aaa	aac	144	
Phe	Lys	Ala	Arg	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Lys	Leu	Lys	Asn		
														35	40	45

tgg	agt	tgc	agc	tct	cct	gtc	ttc	ccc	ggg	aat	tgg	gac	ctg	agg	ctt	192	
Trp	Ser	Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	Arg	Leu		
															50	55	60

ctc	cag	gtg	agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	gcc	ctg	240		
Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu			
															65	70	75	80

acg ctg aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc	288
Thr Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val	
85	90
95	
cta gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag	336
Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln	
100	105
110	
gcc tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc	384
Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg	
115	120
125	
ctc cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc	432
Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser	
130	135
140	
gct ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc	480
Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu	
145	150
155	160
acg cga gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg	528
Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr	
165	170
175	
tca acc cac cct gag tcc acc tga	552
Ser Thr His Pro Glu Ser Thr *	
180	

<210> 151
 <211> 183
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-29 Leu insert after N-terminal Met, C173X

<221> VARIANT
 <222> (173)...(173)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 151
 Met Leu Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly
 1 5 10 15
 Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser
 20 25 30
 Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn
 35 40 45
 Trp Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val
 85 90 95
 Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln
 100 105 110
 Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg
 115 120 125
 Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser
 130 135 140

Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu
 145 150 155 160
 Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr
 165 170 175
 Ser Thr His Pro Glu Ser Thr
 180

<210> 152
 <211> 549
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-29 G2L C172X

<221> variation
 <222> (515)...(516)
 <223> n = A, T, G, or C

<221> CDS
 <222> (1)...(549)

<400> 152
 atg ytn cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc 48
 Met Leu Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
 1 5 10 15

cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc 192
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60

cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg 240
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80

ctg aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc cta 288
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95

gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag gcc 336
 Asp Gln Pro Leu His Thr Leu His Ile Leu Ser Gln Leu Gln Ala
 100 105 110

tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc 384
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125

cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct 432
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140

ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc acg 480

Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
cga gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca			528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser			
165		170	175
acc cac cct gag tcc acc tga			549
Thr His Pro Glu Ser Thr *			
180			

<210> 153
 <211> 182
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-29 G2L C172X

<221> VARIANT
 <222> (172)...(172)
 <223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 153
 Met Leu Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
 1 5 10 15
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30
 Lys Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95
 Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
 100 105 110
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser
 165 170 175
 Thr His Pro Glu Ser Thr
 180

<210> 154
 <211> 552
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> IL-29 Ile insert after N-terminal Met, C173X

<221> variation
 <222> (518)...(519)

<223> n = A, T, G, or C

<221> CDS

<222> (1)...(552)

<400> 154

atg ath ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc 48
 Met Ile Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly
 1 5 10 15

tgc cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc 96
 Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser
 20 25 30

ttc aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac 144
 Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn
 35 40 45

tgg agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt 192
 Trp Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu
 50 55 60

ctc cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg 240
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80

acg ctg aag gtc ctg gag gcc gct gct ggc cca gcc ctg gag gac gtc 288
 Thr Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val
 85 90 95

cta gac cag ccc ctt cac acc ctg cac cac atc ctc tcc cag ctc cag 336
 Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln
 100 105 110

gcc tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc 384
 Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg
 115 120 125

ctc cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc 432
 Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser
 130 135 140

gct ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc 480
 Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu
 145 150 155 160

acg cga gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg 528
 Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr
 165 170 175

tca acc cac cct gag tcc acc tga 552
 Ser Thr His Pro Glu Ser Thr *
 180

<210> 155

<211> 183

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-29 Ile insert after N-terminal Met, C173X

<221> VARIANT

<222> (173) . . . (173)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 155

<210> 156

<211> 549

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 G2I C172X

<222> (515).

<223> n = A, T, G, or C

<221> CDS

<222> (1) . . . (549)

<400> 156

```

atg ath cct gtc ccc act tcc aag ccc acc aca act ggg aag ggc tgc 48
Met Ile Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys
   1           5           10          15

```

cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg agc ttc 96
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30

aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc 192
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60

cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg 240
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80

ctg aag gtc ctg gag gcc gct gtc cca gcc ctg gag gac gtc cta 288
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu
 85 90 95

gac cag ccc ctt cac acc ctg cac atc ctc tcc cag ctc cag gcc 336
 Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala
 100 105 110

tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc 384
 Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu
 115 120 125

cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct 432
 His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala
 130 135 140

ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc ctc acg 480
 Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr
 145 150 155 160

cga gac ctc aaa tat gtg gcc gat ggg aac ctg dnn ctg aga acg tca 528
 Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser
 165 170 175

acc cac cct gag tcc acc tga 549
 Thr His Pro Glu Ser Thr *

180

<210> 157

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-29 G2I C172X

<221> VARIANT

<222> (172)...(172)

<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 157

Met Ile Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys Gly Cys
 1 5 10 15
 His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu

85	90	95
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala		
100	105	110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu		
115	120	125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser		
165	170	175
Thr His Pro Glu Ser Thr		
180		

<210> 158
<211> 531
<212> DNA
<213> Artificial Sequence

<220>
<223> IL-29 after N-terminal Met amino acid residues 2-7
deleted, C166X

<221> variation
<222> (497)...(498)
<223> n = A, T, G, or C

<221> CDS
<222> (1)...(531)

<400> 158			
atg aag ccc acc aca act ggg aag ggc tgc cac att ggc agg ttc aaa			48
Met Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys			
1	5	10	15
tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg gac gcc			96
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala			
20	25	30	
ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct cct gtc			144
Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val			
35	40	45	
ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag cgc cct			192
Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro			
50	55	60	
gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg gag gcc			240
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala			
65	70	75	80
gct gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt cac acc			288
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr			
85	90	95	
ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct cag ccc			336
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro			
100	105	110	
aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg cac cgg			384

Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg			
115	120	125	
ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag gca tct		432	
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser			
130	135	140	
gtc acc ttc aac ctc ttc cgc ctc acg cga gac ctc aaa tat gtg		480	
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val			
145	150	155	160
gcc gat ggg aac ctg dnn ctg aga acg tca acc cac cct gag tcc acc		528	
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr			
165	170	175	
tga		531	
*			

<210> 159
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-29 after N-terminal Met amino acid residues 2-7
deleted, C166X

<221> VARIANT
<222> (166)...(166)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 159
Met Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys
1 5 10 15
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala
20 25 30
Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val
35 40 45
Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro
50 55 60
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala
65 70 75 80
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr
85 90 95
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro
100 105 110
Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg
115 120 125
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser
130 135 140
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val
145 150 155 160
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr
165 170 175

<210> 160
<211> 558
<212> DNA

<213> Artificial Sequence

<220>

<223> IL-29 Glu, Ala, and Glu inserted after N-terminal
Met, C175X

<221> variation

<222> (524)...(525)

<223> n = A, T, G, or C

<221> CDS

<222> (1)...(558)

<400> 160

atg	gar	gcn	gar	ggc	cct	gtc	ccc	act	tcc	aag	ccc	acc	aca	act	ggg	48
Met	Glu	Ala	Glu	Gly	Pro	Val	Pro	Thr	Ser	Lys	Pro	Thr	Thr	Gly		
1	5							10					15			

aag	ggc	tgc	cac	att	ggc	agg	ttc	aaa	tct	ctg	tca	cca	cag	gag	cta	96
Lys	Gly	Cys	His	Ile	Gly	Arg	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	
20								25					30			

gcg	agc	ttc	aag	aag	gcc	agg	gac	gcc	ttg	gaa	gag	tca	ctc	aag	ctg	144
Ala	Ser	Phe	Lys	Lys	Ala	Arg	Asp	Ala	Leu	Glu	Ser	Leu	Lys	Lys	Leu	
35								40					45			

aaa	aac	tgg	agt	tgc	agc	tct	cct	gtc	ttc	ccc	ggg	aat	tgg	gac	ctg	192
Lys	Asn	Trp	Ser	Cys	Ser	Ser	Pro	Val	Phe	Pro	Gly	Asn	Trp	Asp	Leu	
50								55					60			

agg	ctt	ctc	cag	gtg	agg	gag	cgc	cct	gtg	gcc	ttg	gag	gct	gag	ctg	240
Arg	Leu	Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	
65								70					75			

gcc	ctg	acg	ctg	aag	gtc	ctg	gag	gcc	gct	gct	ggc	cca	gcc	ctg	gag	288
Ala	Leu	Thr	Leu	Lys	Val	Leu	Glu	Ala	Ala	Ala	Gly	Pro	Ala	Leu	Glu	
85								90					95			

gac	gtc	cta	gac	cag	ccc	ctt	cac	acc	ctg	cac	cac	atc	ctc	tcc	cag	336
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln	
100								105					110			

ctc	cag	gcc	tgt	atc	cag	cct	cag	ccc	aca	gca	ggg	ccc	agg	ccc	cgg	384
Leu	Gln	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Pro	Arg	
115								120					125			

ggc	cgc	ctc	cac	cac	tgg	ctg	cac	cgg	ctc	cag	gag	gcc	ccc	aaa	aag	432
Gly	Arg	Leu	His	His	Trp	Leu	His	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys	
130								135					140			

gag	tcc	gct	ggc	tgc	ctg	gag	gca	tct	gtc	acc	ttc	aac	ctc	ttc	cgc	480
Glu	Ser	Ala	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145								150					155			

ctc	ctc	acg	cga	gac	ctc	aaa	tat	gtg	gcc	gat	ggg	aac	ctg	dnn	ctg	528
Leu	Leu	Thr	Arg	Asp	Leu	Lys	Tyr	Val	Ala	Asp	Gly	Asn	Leu	Xaa	Leu	
165								170					175			

aga	acg	tca	acc	cac	cct	gag	tcc	acc	tga							558
Arg	Thr	Ser	Thr	His	Pro	Glu	Ser	Thr	*							
180								185								

<210> 161
<211> 185
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-29 Glu, Ala, and Glu inserted after N-terminal
Met, C175X

<221> VARIANT
<222> (175)...(175)
<223> Xaa = Ser, Ala, Thr, Val, or Asn

<400> 161
Met Glu Ala Glu Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Thr Gly
1 5 10 15
Lys Gly Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu
20 25 30
Ala Ser Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu
35 40 45
Lys Asn Trp Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu
50 55 60
Arg Leu Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu
65 70 75 80
Ala Leu Thr Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu
85 90 95
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
100 105 110
Leu Gln Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg
115 120 125
Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys
130 135 140
Glu Ser Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
145 150 155 160
Leu Leu Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Xaa Leu
165 170 175
Arg Thr Ser Thr His Pro Glu Ser Thr
180 185

<210> 162
<211> 528
<212> DNA
<213> Artificial Sequence

<220>
<223> Human IL-28A C2 mutant for expression in E. coli

<221> CDS
<222> (1)...(528)

<221> variation
<222> (146)...(147)
<223> n = A, T, G or C

<400> 162
atg gtt ccg gtt gct cgt ctg cac ggt gct ctg ccg gac gct cgt ggt 48
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
1 5 10 15

tgc cac atc gct cag ttc aaa tct ctg tct ccg cag gaa ctg cag gct	96																																																																																										
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala																																																																																											
20	25	25	30	ttc aaa cgt gct aaa gac gct ctg gaa gaa tct ctg ctg ctg aaa gac	144	Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp		35	40	40	45	dnn cgt tgc cac tct cgt ctg ttc ccg cgt acc tgg gac ctg cgt cag	192	Xaa Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln		50	55	55	60	ctg cag gtt cgt gaa cgt ccg atg gct ctg gaa gct gaa ctg gct ctg	240	Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu		65	70	70	75	75	80	acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288	Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175	
25	30																																																																																										
ttc aaa cgt gct aaa gac gct ctg gaa gaa tct ctg ctg ctg aaa gac	144																																																																																										
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp																																																																																											
35	40	40	45	dnn cgt tgc cac tct cgt ctg ttc ccg cgt acc tgg gac ctg cgt cag	192	Xaa Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln		50	55	55	60	ctg cag gtt cgt gaa cgt ccg atg gct ctg gaa gct gaa ctg gct ctg	240	Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu		65	70	70	75	75	80	acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288	Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175									
40	45																																																																																										
dnn cgt tgc cac tct cgt ctg ttc ccg cgt acc tgg gac ctg cgt cag	192																																																																																										
Xaa Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln																																																																																											
50	55	55	60	ctg cag gtt cgt gaa cgt ccg atg gct ctg gaa gct gaa ctg gct ctg	240	Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu		65	70	70	75	75	80	acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288	Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																	
55	60																																																																																										
ctg cag gtt cgt gaa cgt ccg atg gct ctg gaa gct gaa ctg gct ctg	240																																																																																										
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu																																																																																											
65	70	70	75	75	80	acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288	Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																									
70	75	75	80	acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288	Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																											
75	80																																																																																										
acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288																																																																																										
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val																																																																																											
85	90	90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																			
90	95	95		gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336	Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																					
95																																																																																											
gac gtt ctg gac cag ccg ctg cac acc ctg cac atc ctg tct cag	336																																																																																										
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln																																																																																											
100	105	105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																													
105	110	110		ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384	Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																															
110																																																																																											
ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384																																																																																										
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg																																																																																											
115	120	120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																							
120	125	125		ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432	Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																									
125																																																																																											
ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432																																																																																										
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys																																																																																											
130	135	135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																																	
135	140	140		gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480	Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																																			
140																																																																																											
gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480																																																																																										
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg																																																																																											
145	150	150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																																											
150	155	155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																																													
155	160	160		ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528	Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		165	170	170	175	175																																																																															
160																																																																																											
ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528																																																																																										
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val																																																																																											
165	170	170	175	175																																																																																							
170	175	175																																																																																									
175																																																																																											

<210> 163
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> Human IL-28A C2 mutant for expression in E. coli

<221> VARIANT
<222> (49)...(49)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 163
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly
1 5 10 15
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
20 25 30
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Leu Lys Asp

35	40	45
Xaa Arg Cys His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln		
50	55	60
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu		
65	70	75
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val		80
85	90	95
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln		
100	105	110
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg		
115	120	125
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys		
130	135	140
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg		
145	150	155
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val		160
165	170	175

<210> 164

<211> 528

<212> DNA

<213> Artificial Sequence

<220>

<223> Human IL-28A C3 mutant for expression in E. coli

<221> CDS

<222> (1)...(528)

<221> variation

<222> (152)...(153)

<223> n = A, T, G or C

<400> 164

atg gtt ccg gtt gct cgt ctg cac ggt gct ctg ccg gac gct cgt ggt	48
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly	
1	5
	10
	15

tgc cac atc gct cag ttc aaa tct ctg tct ccg cag gaa ctg cag gct	96
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala	
20	25
	30

ttc aaa cgt gct aaa gac gct ctg gaa gaa tct ctg ctg ctg aaa gac	144
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp	
35	40
	45

tgc cgt dnn cac tct cgt ctg ttc ccg cgt acc tgg gac ctg cgt cag	192
Cys Arg Xaa His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln	
50	55
	60

ctg cag gtt cgt gaa cgt ccg atg gct ctg gaa gct gaa ctg gct ctg	240
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu	
65	70
	75
	80

acc ctg aaa gtt ctg gaa gct acc gct gac acc gac ccg gct ctg gtt	288
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val	
85	90
	95

gac gtt ctg gac cag ccg ctg cac acc ctg cac cac atc ctg tct cag	336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	

100 105 110

ttc cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg	
115 120 125	
ggt cgt ctg cac cac tgg ctg tac cgt ctg cag gaa gct ccg aaa aaa	432
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	

<210> 165
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> Human IL-28A C3 mutant for expression in E. coli

<221> VARIANT
<222> (51)...(51)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 165	
Met Val Pro Val Ala Arg Leu His Gly Ala Leu Pro Asp Ala Arg Gly	
1 5 10 15	
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala	
20 25 30	
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp	
35 40 45	
Cys Arg Xaa His Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln	
50 55 60	
Leu Gln Val Arg Glu Arg Pro Met Ala Leu Glu Ala Glu Leu Ala Leu	
65 70 75 80	
Thr Leu Lys Val Leu Glu Ala Thr Ala Asp Thr Asp Pro Ala Leu Val	
85 90 95	
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	
100 105 110	
Phe Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg	
115 120 125	
Gly Arg Leu His His Trp Leu Tyr Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	

<210> 166
<211> 528
<212> DNA
<213> Artificial Sequence

<220>

<223> Human IL-28B C2 mutant for expression in E. coli

<221> CDS

<222> (1)...(528)

<221> variation

<222> 146, 147, 264

<223> n = A, T, G or C

<400> 166

atg	gtt	ccg	gtt	gct	cgt	ctg	cgt	ggt	gct	ctg	ccg	gac	gct	cgt	ggt		48
Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly		
1	5					10					15						

tgc	cac	atc	gct	cag	ttc	aaa	tct	ctg	tct	ccg	cag	gaa	ctg	cag	gct		96
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala		
20						25					30						

ttc	aaa	cgt	gct	aaa	gac	gct	ctg	gaa	gaa	tct	ctg	ctg	aaa	gac		144
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp		
35						40					45					

dnn	aaa	tgc	cgt	tct	cgt	ctg	ttc	ccg	cgt	acc	tgg	gac	ctg	cgt	cag		192
Xaa	Lys	Cys	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln		
50						55					60						

ctg	cag	gtt	cgt	gaa	cgt	ccg	gtt	gct	ctg	gaa	gct	ctg	gct	ctg		240
Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu	
65						70			75		80					

acc	ctg	aaa	gtt	ctg	gaa	gct	wsn	gct	gac	acc	gac	ccg	gct	ctg	ggt		288
Thr	Leu	Lys	Val	Leu	Glu	Ala	Xaa	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly		
85						90			95								

gac	gtt	ctg	gac	cag	ccg	ctg	cac	acc	ctg	cac	cac	atc	ctg	tct	cag		336
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln		
100						105			110								

ctg	cgt	gct	tgc	atc	cag	ccg	cag	ccg	acc	gct	ggt	ccg	cgt	acc	cgt		384
Leu	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg		
115						120			125								

ggt	cgt	ctg	cac	cac	tgg	ctg	yay	cgt	ctg	cag	gaa	gct	ccg	aaa	aaa		432
Gly	Arg	Leu	His	His	Trp	Leu	Xaa	Arg	Leu	Gln	Ala	Pro	Lys	Lys			
130						135			140								

gaa	tct	ccg	ggt	tgc	ctg	gaa	gct	tct	gtt	acc	ttc	ctg	ttc	cgt		480
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg	
145						150			155		160					

ctg	ctg	acc	cgt	gac	ctg	aac	tgc	gtt	gct	tct	ggt	gac	ctg	tgc	gtt		528
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val		
165						170			175								

<210> 167

<211> 176

<212> PRT

<213> Artificial Sequence

<220>

<223> Human IL-28B C2 mutant for expression in E. coli

<221> VARIANT

<222> (49)...(49)

<223> Xaa = Ser, Ala, Thr, Val or Asn

<221> VARIANT

<222> (88)...(88)

<223> Xaa = Thr or Ser

<221> VARIANT

<222> (136)...(136)

<223> Xaa = His or Tyr

<400> 167

Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly
1				5			10					15			
Cys	His	Ile	Ala	Gln	Phe	Lys	Ser	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Ala
		20					25					30			
Phe	Lys	Arg	Ala	Lys	Asp	Ala	Leu	Glu	Glu	Ser	Leu	Leu	Lys	Asp	
		35					40					45			
Xaa	Lys	Cys	Arg	Ser	Arg	Leu	Phe	Pro	Arg	Thr	Trp	Asp	Leu	Arg	Gln
	50					55						60			
Leu	Gln	Val	Arg	Glu	Arg	Pro	Val	Ala	Leu	Glu	Ala	Glu	Leu	Ala	Leu
	65			70					75				80		
Thr	Leu	Lys	Val	Leu	Glu	Ala	Xaa	Ala	Asp	Thr	Asp	Pro	Ala	Leu	Gly
		85					90					95			
Asp	Val	Leu	Asp	Gln	Pro	Leu	His	Thr	Leu	His	His	Ile	Leu	Ser	Gln
		100					105					110			
Leu	Arg	Ala	Cys	Ile	Gln	Pro	Gln	Pro	Thr	Ala	Gly	Pro	Arg	Thr	Arg
		115					120					125			
Gly	Arg	Leu	His	His	Trp	Leu	Xaa	Arg	Leu	Gln	Glu	Ala	Pro	Lys	Lys
	130					135					140				
Glu	Ser	Pro	Gly	Cys	Leu	Glu	Ala	Ser	Val	Thr	Phe	Asn	Leu	Phe	Arg
	145				150				155				160		
Leu	Leu	Thr	Arg	Asp	Leu	Asn	Cys	Val	Ala	Ser	Gly	Asp	Leu	Cys	Val
					165				170				175		

<210> 168

<211> 528

<212> DNA

<213> Artificial Sequence

<220>

<223> Human IL-28B C3 mutant for expression in E. coli

<221> CDS

<222> (1)...(528)

<221> variation

<222> 152, 153, 264

<223> n = A, T, G or C

<400> 168

atg	gtt	ccg	gtt	gtc	cgt	ctg	cgt	ggt	gct	ctg	ccg	gac	gct	cgt	ggt
1				5				10				15			48
Met	Val	Pro	Val	Ala	Arg	Leu	Arg	Gly	Ala	Leu	Pro	Asp	Ala	Arg	Gly

tgc cac atc gct cag ttc aaa tct ctg tct ccg cag gaa ctg cag gct	96
Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala	
20 25 30	
ttc aaa cgt gct aaa gac gct ctg gaa gaa tct ctg ctg aaa gac	144
Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp	
35 40 45	
tgc aaa dnn cgt tct cgt ctg ttc ccg cgt acc tgg gac ctg cgt cag	192
Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln	
50 55 60	
ctg cag gtt cgt gaa cgt ccg gtt gct ctg gaa gct gaa ctg gct ctg	240
Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu	
65 70 75 80	
acc ctg aaa gtt ctg gaa gct wsn gct gac acc gac ccg gct ctg ggt	288
Thr Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly	
85 90 95	
gac gtt ctg gac cag ccg ctg cac acc ctg cac atc atc ctg tct cag	336
Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln	
100 105 110	
ctg cgt gct tgc atc cag ccg cag ccg acc gct ggt ccg cgt acc cgt	384
Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg	
115 120 125	
ggt cgt ctg cac cac tgg ctg yay cgt ctg cag gaa gct ccg aaa aaa	432
Gly Arg Leu His His Trp Leu Xaa Arg Leu Gln Glu Ala Pro Lys Lys	
130 135 140	
gaa tct ccg ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt	480
Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg	
145 150 155 160	
ctg ctg acc cgt gac ctg aac tgc gtt gct tct ggt gac ctg tgc gtt	528
Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val	
165 170 175	

<210> 169
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> Human IL-28B C3 mutant for expression in E. coli

<221> VARIANT
<222> (51)...(51)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<221> VARIANT
<222> (88)...(88)
<223> Xaa = Thr or Ser

<221> VARIANT
<222> (136)...(136)

<223> Xaa = His or Tyr

<400> 169

Met Val Pro Val Ala Arg Leu Arg Gly Ala Leu Pro Asp Ala Arg Gly
 1 5 10 15
 Cys His Ile Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala
 20 25 30
 Phe Lys Arg Ala Lys Asp Ala Leu Glu Glu Ser Leu Leu Lys Asp
 35 40 45
 Cys Lys Xaa Arg Ser Arg Leu Phe Pro Arg Thr Trp Asp Leu Arg Gln
 50 55 60
 Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu
 65 70 75 80
 Thr Leu Lys Val Leu Glu Ala Xaa Ala Asp Thr Asp Pro Ala Leu Gly
 85 90 95
 Asp Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln
 100 105 110
 Leu Arg Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Thr Arg
 115 120 125
 Gly Arg Leu His His Trp Leu Xaa Arg Leu Gln Glu Ala Pro Lys Lys
 130 135 140
 Glu Ser Pro Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg
 145 150 155 160
 Leu Leu Thr Arg Asp Leu Asn Cys Val Ala Ser Gly Asp Leu Cys Val
 165 170 175

<210> 170

<211> 549

<212> DNA

<213> Artificial Sequence

<220>

<223> Human IL-29 C1 mutant for expression in E. coli

<221> CDS

<222> (1)...(549)

<221> variation

<222> 33, 47, 48, 57

<223> n = A, T, G or C

<400> 170

atg ggt ccg gtt ccg acc tct aaa cca acc mcn act ggt aaa ggt dnn 48
 Met Gly Pro Val Pro Thr Ser Lys Pro Thr Xaa Thr Gly Lys Gly Xaa
 1 5 10 15

cac atc grn cgt ttc aaa tct ctg tct ccg cag gaa ctg gct tct ttc 96
 His Ile Xaa Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30

aaa aaa gct cgt gac gct ctg gaa gaa tct ctg aaa ctg aaa aac tgg 144
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45

tct tgc tct tct ccg gtt ttc ccg ggt aac tgg gat ctg cgt ctg ctg 192
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60

cag gtt cgt gaa cgt ccg gtt gct ctg gaa gct gaa ctg gct ctg acc 240
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr

65	70	75	80	
ctg aaa gtt ctg gaa gct gct gca ggt cct gct ctg gaa gat gtt ctg				288
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu				
85	90	95		
gat cag ccg ctg cac act ctg cac cac atc ctg tct cag ctg cag gct				336
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala				
100	105	110		
tgc att caa ccg caa ccg acc gct ggt ccg cgt ccg cgt ggt cgt ctg				384
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu				
115	120	125		
cac cac tgg ctg cat cgt ctg cag gaa gct ccg aaa aaa gaa tct gct				432
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala				
130	135	140		
ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt ctg ctg acc				480
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr				
145	150	155	160	
cgt gat ctg aaa tac gtt gct gat ggt ray ctg tgc ctg cgt acc tct				528
Arg Asp Leu Lys Tyr Val Ala Asp Gly Xaa Leu Cys Leu Arg Thr Ser				
165	170	175		
acc cat ccg gaa tct acc taa				549
Thr His Pro Glu Ser Thr *				
180				

<210> 171

<211> 182

<212> PRT

<213> Artificial Sequence

<220>

<223> Human IL-29 C1 mutant for expression in E. coli

<221> VARIANT

<222> (11)...(11)

<223> Xaa = Thr or Pro

<221> VARIANT

<222> (16)...(16)

<223> Xaa = Ser, Ala, Thr, Val or Asn

<221> VARIANT

<222> (19)...(19)

<223> Xaa = Gly or Asp

<221> VARIANT

<222> (170)...(170)

<223> Xaa = Asn or Asp

<400> 171

Met Gly Pro Val Pro Thr Ser Lys Pro Thr Xaa Thr Gly Lys Gly Xaa

1 5 10 15

His Ile Xaa Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe

20 25 30

Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp

35	40	45	
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu			
50	55	60	
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu			
85	90	95	
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
Arg Asp Leu Lys Tyr Val Ala Asp Gly Xaa Leu Cys Leu Arg Thr Ser			
165	170	175	
Thr His Pro Glu Ser Thr			
180			

<210> 172

<211> 549

<212> DNA

<213> Artificial Sequence

<220>

<223> Human IL-29 C5 mutant for expression in E. coli

<221> CDS

<222> (1)...(549)

<221> variation

<222> 33, 57, 515, 516

<223> n = A, T, G or C

<400> 172

atg ggt ccg gtt ccg acc tct aaa cca acc mcn act ggt aaa ggt tgc	48		
Met Gly Pro Val Pro Thr Ser Lys Pro Thr Xaa Thr Gly Lys Gly Cys			
1	5	10	15

cac atc grn cgt ttc aaa tct ctg tct ccg cag gaa ctg gct tct ttc	96	
His Ile Xaa Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe		
20	25	30

aaa aaa gct cgt gac gct ctg gaa tct ctg aaa ctg aaa aac tgg	144	
Lys Lys Ala Arg Asp Ala Leu Glu Ser Leu Lys Leu Lys Asn Trp		
35	40	45

tct tgc tct tct ccg gtt ttc ccg ggt aac tgg gat ctg cgt ctg	192	
Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu		
50	55	60

cag gtt cgt gaa cgt ccg gtt gct ctg gaa gct gaa ctg gct ctg acc	240		
Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr			
65	70	75	80

ctg aaa gtt ctg gaa gct gct gca ggt cct gct ctg gaa gat gtt ctg	288	
Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu		
85	90	95

gat cag ccg ctg cac act ctg cac cac atc ctg tct cag ctg cag gct	336		
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala			
100	105	110	
tgc att caa ccg caa ccg acc gct ggt ccg cgt ccg cgt ggt cgt ctg	384		
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu			
115	120	125	
cac cac tgg ctg cat cgt ctg cag gaa gct ccg aaa aaa gaa tct gct	432		
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala			
130	135	140	
ggt tgc ctg gaa gct tct gtt acc ttc aac ctg ttc cgt ctg ctg acc	480		
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr			
145	150	155	160
cgt gat ctg aaa tac gtt gct gat ggt ray ctg dnn ctg cgt acc tct	528		
Arg Asp Leu Lys Tyr Val Ala Asp Gly Xaa Leu Xaa Leu Arg Thr Ser			
165	170	175	
acc cat ccg gaa tct acc taa	549		
Thr His Pro Glu Ser Thr *			
180			

<210> 173
 <211> 182
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Human IL-29 C5 mutant for expression in E. coli

<221> VARIANT
 <222> (11)...(11)
 <223> Xaa = Thr or Pro

<221> VARIANT
 <222> (19)...(19)
 <223> Xaa = Gly or Asp

<221> VARIANT
 <222> (170)...(170)
 <223> Xaa = Asp or Asn

<221> VARIANT
 <222> (172)...(172)
 <223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 173
 Met Gly Pro Val Pro Thr Ser Lys Pro Thr Xaa Thr Gly Lys Gly Cys
 1 5 10 15
 His Ile Xaa Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe
 20 25 30
 Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp
 35 40 45
 Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu
 50 55 60
 Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr
 65 70 75 80
 Leu Lys Val Leu Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu

85	90	95
Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala		
100	105	110
Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu		
115	120	125
His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala		
130	135	140
Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr		
145	150	155
Arg Asp Leu Lys Tyr Val Ala Asp Gly Xaa Leu Xaa Leu Arg Thr Ser		
165	170	175
Thr His Pro Glu Ser Thr		
180		

<210> 174

<211> 531

<212> DNA

<213> Artificial Sequence

<220>

<223> Human IL-29 d2/7 C5 mutant for expression in E. coli

<221> CDS

<222> (1)...(531)

<221> variation

<222> (497)...(498)

<223> n = A, T, G or C

<400> 174

atg aaa cca acc acc act ggt aaa ggt tgc cac atc ggt cgt ttc aaa		48
Met Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys		
1	5	10
		15

tct ctg tct ccg cag gaa ctg gct tct ttc aaa aaa gct cgt gac gct		96
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala		
20	25	30

ctg gaa gaa tct ctg aaa ctg aaa aac tgg tct tgc tct tct ccg gtt		144
Leu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val		
35	40	45

ttc ccg ggt aac tgg gat ctg cgt ctg cag gtt cgt gaa cgt ccg		192
Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro		
50	55	60

gtt gct ctg gaa gct gaa ctg gct ctg acc ctg aaa gtt ctg gaa gct		240
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala		
65	70	75
		80

gct gca ggt cct gct ctg gaa gat gtt ctg gat cag ccg ctg cac act		288
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr		
85	90	95

ctg cac cac atc ctg tct cag ctg cag gct tgc att caa ccg caa ccg		336
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro		
100	105	110

acc gct ggt ccg cgt ccg cgt ggt cgt ctg cac cac tgg ctg cat cgt		384
---	--	-----

Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg			
115	120	125	
ctg cag gaa gct ccg aaa aaa gaa tct gct ggt tgc ctg gaa gct tct		432	
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser			
130	135	140	
gtt acc ttc aac ctg ttc cgt ctg acc cgt gat ctg aaa tac gtt		480	
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val			
145	150	155	160
gct gat ggt aac ctg dnn ctg cgt acc tct acc cat ccg gaa tct acc		528	
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr			
165	170	175	
taa		531	
*			

<210> 175
<211> 176
<212> PRT
<213> Artificial Sequence

<220>
<223> Human IL-29 d2/7 C5 mutant for expression in E.
coli

<221> VARIANT
<222> (166)...(166)
<223> Xaa = Ser, Ala, Thr, Val or Asn

<400> 175
Met Lys Pro Thr Thr Gly Lys Gly Cys His Ile Gly Arg Phe Lys
1 5 10 15
Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg Asp Ala
20 25 30
Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser Pro Val
35 40 45
Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu Arg Pro
50 55 60
Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu Glu Ala
65 70 75 80
Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu His Thr
85 90 95
Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro Gln Pro
100 105 110
Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg
115 120 125
Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu Ala Ser
130 135 140
Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys Tyr Val
145 150 155 160
Ala Asp Gly Asn Leu Xaa Leu Arg Thr Ser Thr His Pro Glu Ser Thr
165 170 175